卵巢癌耐药细胞与非耐药细胞差异表达基因的验证与结构和表型变化研究
|
摘要
卵巢上皮癌在妇科恶性肿瘤中致死率最高。手术后,以铂类为基础的联合化疗是其主要的治疗方法。但随着化疗的进行,患者最终获得难以治愈的多药耐药,因而其五年生存率一直徘徊在30-50%。为了更好地认识肿瘤抑制基因在卵巢癌多药耐药中的机制,我们对卵巢癌卡铂耐药基因差异表达谱芯片进行了肿瘤抑制基因的筛选及验证,对相关的肿瘤抑制基因启动子区进行了甲基化检测以及突变基因筛选研究。并在组织标本中进行了临床意义的探讨。
第二章卵巢癌卡铂耐药细胞与非耐药细胞差异表达基因的验证
目的:筛选卵巢癌卡铂耐药表达谱基因芯片中卡铂耐药细胞系(SKOV3-CB)较其亲本(SKOV3)细胞系差异表达下调的肿瘤抑制基因,并验证其差异表达。
方法:应用分子生物信息学方法,分析卵巢癌卡铂耐药表达谱基因芯片中卵巢癌SKOV3-CB细胞系较SKOV3细胞系差异表达下调两倍以上的基因1554条,筛选肿瘤抑制基因。应用real-time PCR技术对基因芯片中差异表达基因检测验证。
结果:从卵巢癌卡铂耐药表达谱基因芯片中筛选出RNASET2,VHL,DLG1,COPS2,NOL7,GGNBP2, RBL1, S100A2, PARG1,PERP,TCF3,DNAJA3,PCGF2,ING1,CYLD,RARRES3,RBBP8等17个肿瘤抑制基因,荧光定量PCR技术差异表达验证结果示:RNASET2,VHL, COPS2,NOL7, RBL1, S100A2, PARG1,PERP,TCF3,DNAJA3, ING1,CYLD,RARRES3,RBBP8等基因差异表达下调,下调倍数分别为24.47、65.24、10.81、21.30、72.94、5.95、27.13、1.57、1.32、12.93、46.8、7.57、14.9、14. 00、23.98。GGNBP2,PCGF2,DLG1等基因差异表达上调,上调倍数分别为5.76,2.19,17.1,基因芯片差异表达结果与real-time PCR所验证表达下降趋势的结果一致率为82.35%,下调两倍以上的基因一致率为64.70%。
结论:利用基因芯片技术分析基因差异表达结合real-time PCR对其检测结果验证是一种有效的方法,多肿瘤抑制基因参与卵巢癌卡铂耐药的机制。
第三章卵巢癌卡铂耐药细胞与非耐药细胞差异表达基因甲基化检测
目的:探讨卵巢癌卡铂耐药相关肿瘤抑制基因启动子区甲基化状态与卵巢癌卡铂耐药表达下调的关系。
方法:应用分子生物信息学方法,分析肿瘤抑制基因启动子区CPG岛并设计出引物,采用甲基化特异性PCR(MS-PCR)法或亚硫酸盐测序法(bisulphite sequencing)检测SKOV3-CB、SKOV3中的耐药相关肿瘤抑制基因启动子区甲基化状态。
结果:表达下调的14个基因(VHL, COPS2, NOL7,RANSET2, RBL1, S100A2, PARG1, PERP, TCF3, DNAJA3, ING1, RARRES3, RBBP8,CYLD)中,有10个基因(VHL, COPS2, NOL7, RBL1, PARG1, PERP, DNAJA3, ING1, RNASET2,CYLD)启动子区能够设计出引物,其中CYLD未检出结果,后改用亚硫酸盐测序法检测。MS-PCR检测结果显示,SKOV3-CB、SKOV3的ING1、DNAJA3、VHL甲基化引物均能够扩增出产物,未甲基化引物均不能扩增出产物;COPS2、PERP甲基化引物均不能够扩增出产物,未甲基化引物均能够扩增出产物;RNASET2,PARG1、NOL7、RBL1甲基化引物与未甲基化引物均能够扩增出产物,CYLD重亚硫酸盐测序提示在SKOV3-CB及SKOV3细胞系均为未甲基化状态。
结论:卵巢癌卡铂耐药相关肿瘤抑制基因启动子区无超甲基化,甲基化机制不是引起卵巢癌卡铂耐药相关肿瘤抑制基因差异表达下调的原因。
第四章卵巢癌卡铂耐药细胞与非耐药细胞差异表达基因突变检测
目的:筛查可能的基因突变,探讨其与卵巢卡铂耐药以及相关肿瘤抑制基因表达下调的关系。
方法:以亲本细胞系(SKOV3)为对照,在卵巢癌卡铂耐药细胞系(SKOV3-CB),应用单链构象多态性分析(SSCP)检测RNASET2,VHL, COPS2, NOL7, PARG1, RBL1, PERP, DNAJA3, ING1, CYLD等10个基因RT-PCR扩增片段的突变。
结果:以SKOV3细胞系为对照,在SKOV3-CB细胞系中,SSCP检测发现DNAJA3,PERP基因聚丙烯酰胺电泳带型存在差异;RNASET2,VHL,COPS2, NOL7, PARG1, RBL1,ING1, CYLD等基因未检测到差异带型。经测序发现PERP第三外显子1093,1160,1222位点上分别存在A→G突变;1083位点及1085,1086位点,分别存在T,C,C,碱基缺失。DNAJA3第八个外显子87位点处存在A→T突变。
结论:DNAJA3,PERP的基因突变以及PERP基因的碱基缺失与卵巢癌卡铂耐药相关,可能是导致其表达下调的原因,宜进一步深入研究。
第五章卵巢癌卡铂耐药相关肿瘤抑制基因表达与临床病理的关系的研究
目的:探讨卵巢癌卡铂耐药相关肿瘤抑制基因表达的临床意义
方法:Trizol一步法提取卵巢肿瘤患者卵巢组织总RNA,应用RT-PCR检测85例卵巢组织的RNASET2、VHL、PARG1、CYLD、COPS2、PERP、DNAJA3、ING1、NOL7、RBL1基因mRNA表达,其中卵巢癌49例,卵巢良性组织21例,卵巢正常组织15例。
结果: RT-PCR结果显示RNASET2、ING1、PARG 1、RBL1、NOL7基因在正常卵巢组织、卵巢良性肿瘤组织、卵巢癌组织中均有一定程度表达;VHL、PERP、COPS2、CYLD基因在正常卵巢组织、良性肿瘤中、卵巢癌组织中均有一定程度表达,但在部分卵巢癌组织中表达沉默,分别为4(4/49)、3(3/49)、2(2/49)、32(32/49)例;采用Fisher确切概率法统计分析,提示RNASET2、ING1、PARG 1、RBL1、NOL7、VHL、PERP、COPS2基因在卵巢癌中的表达沉默阳性率与在卵巢正常组织及卵巢良性肿瘤中的表达沉默阳性率比较差异无意义。CYLD、DNAJA3基因在卵巢癌中的表达沉默阳性率与在卵巢良性肿瘤组织与正常卵巢组织中的表达沉默阳性率比较差异有显著意义(P分别为0.00、0.00;0.00,0.00)。VHL等10个基因表达与卵巢癌临床病理的关系Fisher确切概率法统计分析,提示CYLD在FIGO I-II与III-IV期存在差异有意义外(P<0.05),其余基因差异均无意义(P均>0.05)。Log Rank分析发现卵巢癌组织VHL、PERP、CYLD基因表达阳性患者与阴性患者的生存时间比较,差异均无统计学意义(P分别为0.183、0.493、0.271)。COPS2基因表达阳性患者与阴性患者的生存时间比较,差异有统计学意义(P=0.005)。COX回归模型多因素生存分析提示FIGO分期、病理分级进入模型(P分别为0.045、0.028);淋巴结转移及COPS2、PERP、CYLD、ING1基因表达沉默等参数均未进入模型(P分别为0.907、0.476、0.754、0.728、0.304)。
结论:结论CYLD、DNAJA3基因表达沉默可作为卵巢癌与卵巢良性肿瘤及正常卵巢组织鉴别诊断的一个潜在的指标,COPS2、PERP、CYLD、ING1不能作为卵巢癌独立的预后因素。
Mortality of epithelial ovarian cancinoma is highest in gynecological malignant tumor. After the surgery, chemotherapy is the major treatment methods based on the combination of platinum chemotherapy. But ultimately, it is difficult to cure patients because of resistance to ovarian carcinoma.So its 5 years survival rate is always 30-50%. In order to better understand the mechanism of tumor suppressor genes in multi-drug resistance of ovarian cancinoma ,tumor suppressor genes related to carboplatin resistance were selected and verified from carboplatin resistance microarray. Promoter region methylation were detected and gene mutation were screened for tumor suppressor genes related to carbo-resistance.Clinical implication of tumor suppressor genes were futher explored in ovarian carcinoma tissue .
Part two Verification of differential expression genes between carbo-resistance cell line and its parental cell line of ovarian carcinoma
Objective: To select tumor suppressor gene from carboplatin resistance microarray , which its downregulation expression were verified between SKOV3 carboplatin resistance cell line and its parental SKOV3 cell line .
Methods: tumor suppressor genes were selected from carboplatin resistance microarray ,which 1554 genes were analysized by bioinformation methods. differential expression of tumor suppressor gene which were two more folds in microarray between resistance SKOV3 cell line and SKOV3 cell lines were verified respectively using real-time RT-PCR。
Results: . 17 tumor suppressor genes which were RNASET2,VHL,DLG1,COPS2,NOL7,GGNBP2, RBL1, S100A2, PARG1,PERP,TCF3,DNAJA3,PCGF2,ING1,CYLD,RARRES3,RBBP8 were selected from the microarray.Of those,differential expression of genes such as RNASET2,VHL, COPS2,NOL7, RBL1, S100A2, PARG1,PERP,TCF3,DNAJA3, ING1,CYLD,RARRES3,RBBP8 were downregulation whose folds were respectively 24.47、65.24、10.81、21.30、72.94、5.95、27.13、1.57、1.32、12.93、46.8、7.57、14.9、14. 00、23.98 .but differential expression of the three genes such as GGNBP2,PCGF2,DLG1 were upregulaion whose folds were 8.0,7.23,1.24 respectively. Accordance rate of the differential experssion downregulation result which were one more folds and two more folds between experimental verification to microarray and microarray respectively were 82.35%,64.70%。
Conclusion:It is a effective method to analyse differential expression of gene which the results were verificated to microarray by real-time PCR technology and multiple tumor suppressor gene involved in the mechanism of resistance of ovarian carcinoma.
Part three Methylation detection of differential expression gene between carbo- resistance cell line and parental cell line of ovarian carcinoma
Objective: To observe the tumor suppressor gene promoter methylation status related to carboplatin resistance of ovarian carcinoma and explore its relationship with expression downregulation in carboplatin resistance of ovarian carcinoma.
Methods: Using molecular bioinformatics methods, promoter CPG island of tumor suppressor gene were analysized to design primers for MS-PCR or bisulphite sequencing .And promoter methylation status of tumor suppressor genes associated with carboplatin resistance were detected between SKOV3-CB and SKOV3 cell line of ovarian carcinoma using methylation-specific PCR (MS-PCR) or bisulphite sequencing method.
Results: 14 genes (VHL, COPS2, NOL7, GGNBP2, RBL1, S100A2, PARG1, PERP, TCF3, DNAJA3, ING1, RARRES3, RBBP8,CYLD) whose differential expressions were downregulation in SKOV3-CB cell line comparing with SKOV3 cell line. Of those ,10 genes (VHL, COPS2, NOL7, RBL1, PARG1, PERP, DNAJA3, ING1, RNASET2,CYLD) could be designed primers for MS-PCR in its promoter region. MS-PCR showed that PCR products of could be amplified by the ING1, DNAJA3, VHL methylation primers and PCR products could not be amplified by the unmethylated primers in both SKOV3-CB andSKOV3 cell line; PCR products could not be amplified by COPS2, PERP methylation primers and PCR products could be amplified by the unmethylated primers in both SKOV3-CB andSKOV3 cell line; PCR products could be amplified by both RNASET2,PARG1、NOL7、RBL1 methylation primers and unmethylated primers in the two cell lines,CYLD which could not be amplified by MS-PCR primers were amplified by bisulphite sequencing and its promoter region were detected to be unmethylated in the two cell lines.
Conclusion: No hypermethylation were detected in promoter region of the tumor suppressor genes related to carboplatin-resistance of ovarian carcinoma ,which differential expression downregulation of the tumor suppressor genes is not caused by methylation mechanism .
Part four Mutation detection of differential expression gene between carboplation resistance and parental cell line of ovarian carcinoma
Objective: Screening of possible genetic mutations, to explore relationship with carboplatin resistance of ovarian and expression downregulation of related tumor suppressor genes
Methods: The parental cell line (SKOV3) as control, in the carboplatin-resistant ovarian cancer cell line (SKOV3-CB), single-strand conformation polymorphism analysis (SSCP) were applied to detect RT-PCR amplified fragments of RNASET2, VHL, COPS2, NOL7, PARG1, RBL1 , PERP, DNAJA3, ING1, CYLD10 genes so as to find genetic mutation.
Results: In the SKOV3-CB cell lines, differential types in polyacrylamide gel electrophoresis of DNAJA3, PERP gene were detected by SSCP in contrast to SKOV3 cell lines, NO differential types of RNASET2, VHL, COPS2, NOL7, PARG1, RBL1, ING1, CYLD genes were detected in polyacrylamide gel electrophoresis between SKOV3-CB and SKOV3 . Respectively there were A→G pot mutation in 1093,1160,1222 locous and T,C,C loss in 1083,1085,1086 locous of the third exon of PERP.There was A→T pot mutation in 87 locous of the sequence of the eighth exon of DNAJA3.
Conclusion: DNAJA3, PERP gene mutation may be related to carboplatin resistance of ovarian carcinoma and to expression downregulation of related tumor suppressor genes . Should be further investigated
Part five The clinical research of expression of related carbo-resistance tumor suppressor genes of ovarian carcinoma
Objective:To investigate the clinical implications of expression of ovarian carcinoma carboplatin resistance-related tumor suppressor gene.
Methods: The total RNA of the ovarian tissues was extracted by one-step Trizol extraction method. Expressions of genes which were RNASET2、VHL、PARG1、CYLD、COPS2、PERP、DNAJA3、ING1、NOL7、RBL1 were detected in ovarian tissues of 85 patients using RT-PCR,which included 49 patients with ovarian carcinoma, 21 patients with benign ovarian tumors,15 patients with normal ovary.
Results:RT-PCR results show that there were expressions of RNASET2、ING1、PARG 1、RBL1、NOL7 gene in ovarian carcinoma tissues ,ovarian benign tumor tissues and normal ovarian tissues and there were expression of VHL、PERP、COPS2、CYLD gene in normal ovarian tissues ,ovarian carcinoma tissues and ovarian benign tumor tissues except expression silence in some ovarian carcinoma tissues which there were 4(4/49)、3(3/49)、2(2/49)、32(32/49)cases respectively.There are no difference for positive ratio of expression silence of RNASET2、ING1、PARG 1、RBL1、NOL7、VHL、PERP、COPS2 gene in between ovarian carcinoma tissues and NOT ovarian carcinoma tissues(P were 1.00、1.00、1.00、1.00、1.00、0.11、0.19、0.33 respectively)and there were difference for Positive ratio of expression silence of CYLD、DNAJA3 gene in between ovarian carcinoma tissues and NOT ovarian carcinoma tissues(P were 0.00、0.00 respectively) with chi square test. There were no difference for survival time between positive expression and negative experrsion of VHL,PERP,CYLD gene (P were 0.183、0.493、0.271 respectively) and there was difference for survival time between positive expression and negative experrsion of COPS2 gene in ovarian carcinoma patients with Log Rank(P=0.005). COX regression show that FIGO stage、differentiation involved in the model(P were 0.045、0.028 respectively)and Lymph node metastasis and expression silence of COPS2、PERP、CYLD、ING1 gene did not involved in the model(P were 0.907、0.476、0.754、0.728、0.304 respectively).
Conclusion:Expression silence of CYLD、DNAJA3 gene maybe were potential marker for differential diagnosis in ovarian tumors and expression silence of COPS2、PERP、CYLD、 ING1 gene were not independent prognostic fators for ovarian carcinoma.
第二章卵巢癌卡铂耐药细胞与非耐药细胞差异表达基因的验证
目的:筛选卵巢癌卡铂耐药表达谱基因芯片中卡铂耐药细胞系(SKOV3-CB)较其亲本(SKOV3)细胞系差异表达下调的肿瘤抑制基因,并验证其差异表达。
方法:应用分子生物信息学方法,分析卵巢癌卡铂耐药表达谱基因芯片中卵巢癌SKOV3-CB细胞系较SKOV3细胞系差异表达下调两倍以上的基因1554条,筛选肿瘤抑制基因。应用real-time PCR技术对基因芯片中差异表达基因检测验证。
结果:从卵巢癌卡铂耐药表达谱基因芯片中筛选出RNASET2,VHL,DLG1,COPS2,NOL7,GGNBP2, RBL1, S100A2, PARG1,PERP,TCF3,DNAJA3,PCGF2,ING1,CYLD,RARRES3,RBBP8等17个肿瘤抑制基因,荧光定量PCR技术差异表达验证结果示:RNASET2,VHL, COPS2,NOL7, RBL1, S100A2, PARG1,PERP,TCF3,DNAJA3, ING1,CYLD,RARRES3,RBBP8等基因差异表达下调,下调倍数分别为24.47、65.24、10.81、21.30、72.94、5.95、27.13、1.57、1.32、12.93、46.8、7.57、14.9、14. 00、23.98。GGNBP2,PCGF2,DLG1等基因差异表达上调,上调倍数分别为5.76,2.19,17.1,基因芯片差异表达结果与real-time PCR所验证表达下降趋势的结果一致率为82.35%,下调两倍以上的基因一致率为64.70%。
结论:利用基因芯片技术分析基因差异表达结合real-time PCR对其检测结果验证是一种有效的方法,多肿瘤抑制基因参与卵巢癌卡铂耐药的机制。
第三章卵巢癌卡铂耐药细胞与非耐药细胞差异表达基因甲基化检测
目的:探讨卵巢癌卡铂耐药相关肿瘤抑制基因启动子区甲基化状态与卵巢癌卡铂耐药表达下调的关系。
方法:应用分子生物信息学方法,分析肿瘤抑制基因启动子区CPG岛并设计出引物,采用甲基化特异性PCR(MS-PCR)法或亚硫酸盐测序法(bisulphite sequencing)检测SKOV3-CB、SKOV3中的耐药相关肿瘤抑制基因启动子区甲基化状态。
结果:表达下调的14个基因(VHL, COPS2, NOL7,RANSET2, RBL1, S100A2, PARG1, PERP, TCF3, DNAJA3, ING1, RARRES3, RBBP8,CYLD)中,有10个基因(VHL, COPS2, NOL7, RBL1, PARG1, PERP, DNAJA3, ING1, RNASET2,CYLD)启动子区能够设计出引物,其中CYLD未检出结果,后改用亚硫酸盐测序法检测。MS-PCR检测结果显示,SKOV3-CB、SKOV3的ING1、DNAJA3、VHL甲基化引物均能够扩增出产物,未甲基化引物均不能扩增出产物;COPS2、PERP甲基化引物均不能够扩增出产物,未甲基化引物均能够扩增出产物;RNASET2,PARG1、NOL7、RBL1甲基化引物与未甲基化引物均能够扩增出产物,CYLD重亚硫酸盐测序提示在SKOV3-CB及SKOV3细胞系均为未甲基化状态。
结论:卵巢癌卡铂耐药相关肿瘤抑制基因启动子区无超甲基化,甲基化机制不是引起卵巢癌卡铂耐药相关肿瘤抑制基因差异表达下调的原因。
第四章卵巢癌卡铂耐药细胞与非耐药细胞差异表达基因突变检测
目的:筛查可能的基因突变,探讨其与卵巢卡铂耐药以及相关肿瘤抑制基因表达下调的关系。
方法:以亲本细胞系(SKOV3)为对照,在卵巢癌卡铂耐药细胞系(SKOV3-CB),应用单链构象多态性分析(SSCP)检测RNASET2,VHL, COPS2, NOL7, PARG1, RBL1, PERP, DNAJA3, ING1, CYLD等10个基因RT-PCR扩增片段的突变。
结果:以SKOV3细胞系为对照,在SKOV3-CB细胞系中,SSCP检测发现DNAJA3,PERP基因聚丙烯酰胺电泳带型存在差异;RNASET2,VHL,COPS2, NOL7, PARG1, RBL1,ING1, CYLD等基因未检测到差异带型。经测序发现PERP第三外显子1093,1160,1222位点上分别存在A→G突变;1083位点及1085,1086位点,分别存在T,C,C,碱基缺失。DNAJA3第八个外显子87位点处存在A→T突变。
结论:DNAJA3,PERP的基因突变以及PERP基因的碱基缺失与卵巢癌卡铂耐药相关,可能是导致其表达下调的原因,宜进一步深入研究。
第五章卵巢癌卡铂耐药相关肿瘤抑制基因表达与临床病理的关系的研究
目的:探讨卵巢癌卡铂耐药相关肿瘤抑制基因表达的临床意义
方法:Trizol一步法提取卵巢肿瘤患者卵巢组织总RNA,应用RT-PCR检测85例卵巢组织的RNASET2、VHL、PARG1、CYLD、COPS2、PERP、DNAJA3、ING1、NOL7、RBL1基因mRNA表达,其中卵巢癌49例,卵巢良性组织21例,卵巢正常组织15例。
结果: RT-PCR结果显示RNASET2、ING1、PARG 1、RBL1、NOL7基因在正常卵巢组织、卵巢良性肿瘤组织、卵巢癌组织中均有一定程度表达;VHL、PERP、COPS2、CYLD基因在正常卵巢组织、良性肿瘤中、卵巢癌组织中均有一定程度表达,但在部分卵巢癌组织中表达沉默,分别为4(4/49)、3(3/49)、2(2/49)、32(32/49)例;采用Fisher确切概率法统计分析,提示RNASET2、ING1、PARG 1、RBL1、NOL7、VHL、PERP、COPS2基因在卵巢癌中的表达沉默阳性率与在卵巢正常组织及卵巢良性肿瘤中的表达沉默阳性率比较差异无意义。CYLD、DNAJA3基因在卵巢癌中的表达沉默阳性率与在卵巢良性肿瘤组织与正常卵巢组织中的表达沉默阳性率比较差异有显著意义(P分别为0.00、0.00;0.00,0.00)。VHL等10个基因表达与卵巢癌临床病理的关系Fisher确切概率法统计分析,提示CYLD在FIGO I-II与III-IV期存在差异有意义外(P<0.05),其余基因差异均无意义(P均>0.05)。Log Rank分析发现卵巢癌组织VHL、PERP、CYLD基因表达阳性患者与阴性患者的生存时间比较,差异均无统计学意义(P分别为0.183、0.493、0.271)。COPS2基因表达阳性患者与阴性患者的生存时间比较,差异有统计学意义(P=0.005)。COX回归模型多因素生存分析提示FIGO分期、病理分级进入模型(P分别为0.045、0.028);淋巴结转移及COPS2、PERP、CYLD、ING1基因表达沉默等参数均未进入模型(P分别为0.907、0.476、0.754、0.728、0.304)。
结论:结论CYLD、DNAJA3基因表达沉默可作为卵巢癌与卵巢良性肿瘤及正常卵巢组织鉴别诊断的一个潜在的指标,COPS2、PERP、CYLD、ING1不能作为卵巢癌独立的预后因素。
Mortality of epithelial ovarian cancinoma is highest in gynecological malignant tumor. After the surgery, chemotherapy is the major treatment methods based on the combination of platinum chemotherapy. But ultimately, it is difficult to cure patients because of resistance to ovarian carcinoma.So its 5 years survival rate is always 30-50%. In order to better understand the mechanism of tumor suppressor genes in multi-drug resistance of ovarian cancinoma ,tumor suppressor genes related to carboplatin resistance were selected and verified from carboplatin resistance microarray. Promoter region methylation were detected and gene mutation were screened for tumor suppressor genes related to carbo-resistance.Clinical implication of tumor suppressor genes were futher explored in ovarian carcinoma tissue .
Part two Verification of differential expression genes between carbo-resistance cell line and its parental cell line of ovarian carcinoma
Objective: To select tumor suppressor gene from carboplatin resistance microarray , which its downregulation expression were verified between SKOV3 carboplatin resistance cell line and its parental SKOV3 cell line .
Methods: tumor suppressor genes were selected from carboplatin resistance microarray ,which 1554 genes were analysized by bioinformation methods. differential expression of tumor suppressor gene which were two more folds in microarray between resistance SKOV3 cell line and SKOV3 cell lines were verified respectively using real-time RT-PCR。
Results: . 17 tumor suppressor genes which were RNASET2,VHL,DLG1,COPS2,NOL7,GGNBP2, RBL1, S100A2, PARG1,PERP,TCF3,DNAJA3,PCGF2,ING1,CYLD,RARRES3,RBBP8 were selected from the microarray.Of those,differential expression of genes such as RNASET2,VHL, COPS2,NOL7, RBL1, S100A2, PARG1,PERP,TCF3,DNAJA3, ING1,CYLD,RARRES3,RBBP8 were downregulation whose folds were respectively 24.47、65.24、10.81、21.30、72.94、5.95、27.13、1.57、1.32、12.93、46.8、7.57、14.9、14. 00、23.98 .but differential expression of the three genes such as GGNBP2,PCGF2,DLG1 were upregulaion whose folds were 8.0,7.23,1.24 respectively. Accordance rate of the differential experssion downregulation result which were one more folds and two more folds between experimental verification to microarray and microarray respectively were 82.35%,64.70%。
Conclusion:It is a effective method to analyse differential expression of gene which the results were verificated to microarray by real-time PCR technology and multiple tumor suppressor gene involved in the mechanism of resistance of ovarian carcinoma.
Part three Methylation detection of differential expression gene between carbo- resistance cell line and parental cell line of ovarian carcinoma
Objective: To observe the tumor suppressor gene promoter methylation status related to carboplatin resistance of ovarian carcinoma and explore its relationship with expression downregulation in carboplatin resistance of ovarian carcinoma.
Methods: Using molecular bioinformatics methods, promoter CPG island of tumor suppressor gene were analysized to design primers for MS-PCR or bisulphite sequencing .And promoter methylation status of tumor suppressor genes associated with carboplatin resistance were detected between SKOV3-CB and SKOV3 cell line of ovarian carcinoma using methylation-specific PCR (MS-PCR) or bisulphite sequencing method.
Results: 14 genes (VHL, COPS2, NOL7, GGNBP2, RBL1, S100A2, PARG1, PERP, TCF3, DNAJA3, ING1, RARRES3, RBBP8,CYLD) whose differential expressions were downregulation in SKOV3-CB cell line comparing with SKOV3 cell line. Of those ,10 genes (VHL, COPS2, NOL7, RBL1, PARG1, PERP, DNAJA3, ING1, RNASET2,CYLD) could be designed primers for MS-PCR in its promoter region. MS-PCR showed that PCR products of could be amplified by the ING1, DNAJA3, VHL methylation primers and PCR products could not be amplified by the unmethylated primers in both SKOV3-CB andSKOV3 cell line; PCR products could not be amplified by COPS2, PERP methylation primers and PCR products could be amplified by the unmethylated primers in both SKOV3-CB andSKOV3 cell line; PCR products could be amplified by both RNASET2,PARG1、NOL7、RBL1 methylation primers and unmethylated primers in the two cell lines,CYLD which could not be amplified by MS-PCR primers were amplified by bisulphite sequencing and its promoter region were detected to be unmethylated in the two cell lines.
Conclusion: No hypermethylation were detected in promoter region of the tumor suppressor genes related to carboplatin-resistance of ovarian carcinoma ,which differential expression downregulation of the tumor suppressor genes is not caused by methylation mechanism .
Part four Mutation detection of differential expression gene between carboplation resistance and parental cell line of ovarian carcinoma
Objective: Screening of possible genetic mutations, to explore relationship with carboplatin resistance of ovarian and expression downregulation of related tumor suppressor genes
Methods: The parental cell line (SKOV3) as control, in the carboplatin-resistant ovarian cancer cell line (SKOV3-CB), single-strand conformation polymorphism analysis (SSCP) were applied to detect RT-PCR amplified fragments of RNASET2, VHL, COPS2, NOL7, PARG1, RBL1 , PERP, DNAJA3, ING1, CYLD10 genes so as to find genetic mutation.
Results: In the SKOV3-CB cell lines, differential types in polyacrylamide gel electrophoresis of DNAJA3, PERP gene were detected by SSCP in contrast to SKOV3 cell lines, NO differential types of RNASET2, VHL, COPS2, NOL7, PARG1, RBL1, ING1, CYLD genes were detected in polyacrylamide gel electrophoresis between SKOV3-CB and SKOV3 . Respectively there were A→G pot mutation in 1093,1160,1222 locous and T,C,C loss in 1083,1085,1086 locous of the third exon of PERP.There was A→T pot mutation in 87 locous of the sequence of the eighth exon of DNAJA3.
Conclusion: DNAJA3, PERP gene mutation may be related to carboplatin resistance of ovarian carcinoma and to expression downregulation of related tumor suppressor genes . Should be further investigated
Part five The clinical research of expression of related carbo-resistance tumor suppressor genes of ovarian carcinoma
Objective:To investigate the clinical implications of expression of ovarian carcinoma carboplatin resistance-related tumor suppressor gene.
Methods: The total RNA of the ovarian tissues was extracted by one-step Trizol extraction method. Expressions of genes which were RNASET2、VHL、PARG1、CYLD、COPS2、PERP、DNAJA3、ING1、NOL7、RBL1 were detected in ovarian tissues of 85 patients using RT-PCR,which included 49 patients with ovarian carcinoma, 21 patients with benign ovarian tumors,15 patients with normal ovary.
Results:RT-PCR results show that there were expressions of RNASET2、ING1、PARG 1、RBL1、NOL7 gene in ovarian carcinoma tissues ,ovarian benign tumor tissues and normal ovarian tissues and there were expression of VHL、PERP、COPS2、CYLD gene in normal ovarian tissues ,ovarian carcinoma tissues and ovarian benign tumor tissues except expression silence in some ovarian carcinoma tissues which there were 4(4/49)、3(3/49)、2(2/49)、32(32/49)cases respectively.There are no difference for positive ratio of expression silence of RNASET2、ING1、PARG 1、RBL1、NOL7、VHL、PERP、COPS2 gene in between ovarian carcinoma tissues and NOT ovarian carcinoma tissues(P were 1.00、1.00、1.00、1.00、1.00、0.11、0.19、0.33 respectively)and there were difference for Positive ratio of expression silence of CYLD、DNAJA3 gene in between ovarian carcinoma tissues and NOT ovarian carcinoma tissues(P were 0.00、0.00 respectively) with chi square test. There were no difference for survival time between positive expression and negative experrsion of VHL,PERP,CYLD gene (P were 0.183、0.493、0.271 respectively) and there was difference for survival time between positive expression and negative experrsion of COPS2 gene in ovarian carcinoma patients with Log Rank(P=0.005). COX regression show that FIGO stage、differentiation involved in the model(P were 0.045、0.028 respectively)and Lymph node metastasis and expression silence of COPS2、PERP、CYLD、ING1 gene did not involved in the model(P were 0.907、0.476、0.754、0.728、0.304 respectively).
Conclusion:Expression silence of CYLD、DNAJA3 gene maybe were potential marker for differential diagnosis in ovarian tumors and expression silence of COPS2、PERP、CYLD、 ING1 gene were not independent prognostic fators for ovarian carcinoma.
引文
[1]连利娟等.林巧稚妇科肿瘤学.北京,人民卫生出版社,2001,p425-p495.
[2]李巍,崔恒.卵巢癌诊断的研究进展,中华妇产科杂志,2005 40(7): 1994-2009.
[3]吴爱如.妇科恶性肿瘤的流行病学,中国肿瘤,1997,6(11):3-5.
[4]葛学顺. CA125、CA199联合检测对卵巢恶性肿瘤的诊断价值[J].检验医学与临床, 2007, 4(3): 177.
[5]蒋冬军,周伟珍.血清CA125联合TSGF、CA199检测在卵巢癌中的临床应用.当代医学,2008,10(7):79-80.
[6]Wu D H,Wu B Y,WangW H. Clinical value of serum CA19-9 and CA72-4 formalignant tumors ofdifferent organ of eldly[J]. China MultOrgan DisEldly, 2003, 2 (1): 561.
[7]庞晓冬.卵巢癌72例的B型超声诊断分析.中国肿瘤临床与康复,2001,8(1):62-63.
[8]汪小芬,何伟。彩超对卵巢癌的诊断价值[J].四川医学, 2009,30 (2):262-263
[9]梁英魁,郭勇.CT和血清肿瘤标记物在卵巢癌诊断和分期中的应用.中国医学影像学杂志,2006,14(2):87-91.
[10]吴湖炳,王全师,王明芳,等.PET/CT显像在探测卵巢癌术后复发、转移中的应用.中华核医学杂志,2006,26(4):197-200.
[11] Bar-shalom R,Valdivia A Y,Blaufox MD.PET imaging in oncology[ J ],Sem in NuclMed,2000,30(3):150-185.
[12]李亚冬,张桂杰。卵巢癌腹水101例脱落细胞学诊断价值[J].中国热带医学,2008,8(5):797-798.
[13]刘冬妍,董艳娥,等.比较血清CEA、CA199、CA125、CA724对卵巢癌临床诊断及疗效观察的价值.辽宁医学杂志,2002,16(1):17-18.
[14] Le T, Adolph A, Krepart GV,et al.The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.Gynecol Oncol, 2002,85(2):351-355
[15] Rubin SC. Surgery for ovarian cancer[J].Hematol Oncol Clin North Am. 1992 ,6(4):851-65.
[16] Takec I. Role of appendectomy in predicting lymph node metastases in patients with ovarian cancer. Eur J Obstet Reprod Biol, 2000,88(2):159-163
[17] Base T,Kosebay D,Kaleli S,etal.Appendectomy in the surgical staging of ovarian carcinoma. Int J Gynaecol Obstet,1996,53(3):249-252.
[18] Fawzi HW, Robertshaw JK, Bolger BS, et al.Role of appendicectomy in the surgical management of ovarian cancer.Eur J Gynaecol Oncol, 1997,18(1):34-35
[19] Kecmanovic DM, Pavlov MJ, Kovacevic PA, et al. Cytoreductive surgery for ovarian cancer. Eur J Surg Oncol,2003 ,29(4):315-320.
[20] Eltabbakh GH, Awtrey CS. Current treatment for ovarian cancer. Expert Opin Pharmacother, 2001 ,2(1):109-124.
[21] Di Re F, Baiocchi G. Value of lymph node assessment in ovarian cancer: Status of the art at the end of the second millennium. Int J Gynecol Cancer, 2000 ,10(6):435-442.
[22] Di Re F, Baiocchi G. Value of lymph node assessment in ovarian cancer: Status of the art at the end of the second millennium. Int J Gynecol Cancer, 2000 ,10(6):435-442.
[23] Yokoyama Y,Sakamoto T,Sato S,etal.Evaluation of cytoruductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer.Eur J Gynaecol Oncol,1999,20(5-6):132-366.
[24]Faught W, Le T, Fung Kee Fung M, et al. Early ovarian cancer: what is the staging impact of retroperitoneal node sampling? J Obstet Gynaecol Can,2003 , 25(1):18-21.
[25]Burghardt E,Pickel H,Lahousen M,et al.Pelvic lymphadenectomy in operative treatment of ovarian cancer.Am J Obstet Gynecol,1986,155(2):315-319.
[26]Kikkawa F,Ishikawa H,Tamakoshi K,et al.Prognostic evaluation of lymphadenectomy for epithelial ovarian cancer.J Surg Oncol,1995,60(4):227-231.
[27]Kigawa J,Minagawa Y,Itamochi H,et al.Retroperitoneal lymphadenectomy,including the para-aortic nodes in patients in patients with stageⅢovarian cancer.Am J Clin Oncol,1994,17(3):230-233.
[28]Saygili U, Guclu S, Uslu T,et al. Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stageⅢovarian carcinoma? A DEGOG Study. J Surg Oncol, 2002 ,81(3):132-137.
[29]Morice P, Camatte S, Wickart-Poque F,et al. Conservative management of malignant and borderline ovarian tumor.Bull Cancer,2002 , 89(12):1019-1026
[30]Morice P,Wicart-Poque F,Rey A,et al.Results of conservative treatment in epithelial ovarian carcinoma.Cancer,2001,92(9):2412-2418.
[31] Plante M.Fertility preservation in the management of gynecologic cancers .Curr Opin Oncol,2000,12:495-497.
[32]Zanetta G,Chiari S,Rota S,et al.Conservative surgery for stage I ovarian canrcinoma in women of childberaring age.Br J Obstet Gynaecal,1997,104(9):1030-1035.
[33]Morice P, Camatte S, Wicart-Poque F ,et al.Results of conservative management of epithelial malignant and borderline ovarian tumours.Hum Reprod Update.,2003,9(2):185-192.
[34]Ayhan A, Celik H, Taskiran C, et al.Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer.Eur J Gynaecol Oncol, 2003,24(3-4):223-232.
[35]Suzuki M , Tsukagoshi S, Ohwada M et al.A patient with brain metastasis from ovarian cancer who showed complete remission after multidisciplinary treatment. Gynecol Oncol ,1999,74(3):483-486.
[36] Piccart M J, Lamb H, Vermorken J B.Current and future potential roles of the platinum drugs in the treatment of ovarian cancer [J].Annals of Oncology, 2001,12(9):1195-1203.
[37] Onnis A ,Marchetti M, Padovan P et al. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynecol Oncol,1996,17:393-396
[38] Munkarrah AR, Hallum AV, Morris M et al.Prognostic significance of residual disease in patients with stageⅣepithelial ovarithelial ovarian cancer. Gynecol Oncol, 1997,64:13-17.
[39] Dauplat J, Bouedec G, Pomel C,et al.Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol ,2000,19(1):42-48.
[40] Tingulstad S, Skjeldestad FE, Hagen B.The effect of centralization of primary surgery on survival in ovarian cancer patients.Obstet Gynecol, 2003 ,102(3):499-505.
[41] Hamid D,Rohr S,Baldauf JJ,et al.Interest in intestinal resection for treatment of advanced ovarian cancer.Ann Chir,2002,127(1):40-47.
[42]Todo Y, Sakuragi N, Oikawa M, et al. Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma.Int J Clin Oncol, 2003 ,8(2):90-96.
[43]Balbi GC,Compagna R,Musone R, et al.Cytoreductive surgery in patients with stage IV ovarian carcinoma.Mineva Gynecol,2001, 53[Suppl 1]:105-109.
[44] Schorge JO, Wingo SN, Bhore R, et al.Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer[J]. Int J Gynaecol Obstet. 2010 Feb;108(2):123-127.
[45] Tian WJ, Jiang R, Cheng X, et al.Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction[J]. J Surg Oncol. 2010 Mar 1;101(3):244-250.
[46]Eisenkop SM, Friedman RL, Spirtos NM.The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.Cancer[J]. 2000, 88(1):144-153.
[47]Bae J, Lim MC, Choi JH, et al.Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer[J]. J Gynecol Oncol. 2009 ,20(2):101-106.
[48]McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].N Engl J Med, 1996, 334:1-6.
[49]Piccart MJ, Bertelsen K, Stuart G, et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophos- phamide-cisplatin combination in advanced ovarian cancer [J].Int J Gynecol Cancer,2003,13(suppl 2):144-148.
[50]Neijt JP,Engelbolm SA,Tuxen MK,et a1.Exploratory phaseⅢstudy of paclitaxd and clsplatin versus paclitaxd and carbo platin in advanced ovarian cancer [J].J Clin Oncol,2000,18(17):3084-3092.
[51]Dubois A,Lueek HJ,Meier W,et al.A randomized clinicaltrial of cisplati paclitaxel versus carboplatinJpaelitaxd as first-line treatment of ovarian cancer [J].J Natl Cancer Inst,2003,95(17):1320-1329
[52]Ozols RF, Brian N,Bundy, et al. Phase III trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study [J]. J Clin Oncol .2003;21:3194-3200
[53]Andreas dB, Hans JL, Werner M. A. Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer [J].J Natl Cancer Inst 2003,95(17):1320–1330.
[54]Muggia F,Braly P,Brady M,et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: Gynecologic Oncology Group study [J]. J Clin Oncol 2000, 18 (1):106-115.
[55]沈铿,李孟达,丰有吉等.泰素周疗和三周疗法作为卵巢癌一线化疗的多中心对照研究[J].中华医学杂志, 2005, 85(30):2099-2013.
[56] Hogberg T.Chemotherapy: Current drugs still have potential in advanced ovarian cancer[J]. Nat Rev Clin Oncol. 2010,7(4):191-193.
[57]Gadducci A,Carnino F,Chiara S,et a1.Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer:a randomized trial of the Gruppo OncologicoNord-Ovest [J].Gynecol Oncol,2000,76(2):157-162.
[58] polyzos A,Tsavaris N,Kosrnas C,at a1.A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stageⅢovarian cancer [J].Oncology,1999,56(1):191-196.
[59]Carrabin N, Mithieux F, Meeus P, et al Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer[J]. Bull Cancer. 2010 ,97(4):E23-32.
[60] Maurie Markman, P.Y. Liu, Sharon Wilczynski, et al.Phase III Randomized Trial of 12 Versus 3 Months ofMaintenance Paclitaxel in Patients With Advanced OvarianCancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial [J].J Clin Oncol, 2003, 21:2460-2465.
[61]Fleming GF,Toth BJ, Baker SD, et al.Phase I trial of aclitaxel and etoposide for recurrent ovarian cancer: a Gynecologic Oncology GroupStudy [J].Am J Clin,2000,23(6):609-613.
[62]Pignata S, Deplacido S, Scambia G, et al.Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer.multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study [J].J Clin Oncol, 2004, 22:2635-2642.
[63]成宁海,黄惠芳,潘凌亚等.晚期卵巢上皮癌的巩固化疗—一项前瞻性随机对照试验[J].解放军医学杂志,2006, 31(7):654-656.
[64] Amikura T, Aoki Y, Kase H, et al. Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy [J].Int J Clin Oncol, 2002, 7(1):45-50.
[65]McLean KA, Shah CA, Thompson SA, et al.Ovarian cancer in the elderly: Outcomes with neoadjuvant chemotherapy or primary cytoreduction[J]. Gynecol Oncol. 2010 Apr 26. [Epub ahead of print]
[66]Weinberg LE, Rodriguez G, Hurteau JA.The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer[J].J Surg Oncol. 2010,101(4):334-343.
[67]Tiersten AD, Moon J, Smith HO, et al.Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study[J]. Oncology. 2009;77(6):395-399.
[68]刘穗,刘继红,黄鹤等.上皮性卵巢癌复发的影响因素分析[J].癌症,2003,22(11):1197-1200.
[69] Pecorelli S, Odicino F, Favalli G.Ovarian cancer:best timing and applications of debulking surgery [J].Ann Oncol, 2000, 11(Suppl 3):141-144.
[70] Chi DS,Liao JB,Leon LF,et al.Identification of prognostic facter in advanced epithelial ovarian carcinoma [J].Gynecol Oneol,2001,82(3):532-537.
[71] Bristow RE,Tomacruz RS,Arm strong DK,et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:ameta-analysis [J].J Clin Oncol,2002,2O:1248-1259
[72]Gore M, Mainwaring PA, Hern R, et al.Randomized trial of dose-intensity with single-agent carboplatin patients with epithelial ovarian cancer [J].J Clin Oncol, 1998, 16(7):2426-2434
[73] Jakobsen A, Bertelsen K, Andersen JE, et al.Dose-Effect Study of Carboplatin in Ovarian Cancer:A Danish Ovarian Cancer Group Study [J].J Clin Oncol, 1997, 15 (1): l93-198.
[74] Kaye SB, Pau1 J, Cassidy J, et al. Mature results of a randomize(1 trial of two doses of cisplatin for the treatment of ovarian cancer.St·0ttish Gynecology Cancer Trials Group [J].J Clin Oncol, 1996, 14(7):21l3-21l9
[75]Conte PF,Bruzzone M,Camino F,et al.High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer:A randomized study of the gono [J].J Clin Oncol,1996,l4(21):351-356
[76] Dittfich CH,Sevelda P,alzer H,et al.Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients.10 year results of a prospective randomised phase III study comparing carboplatin-cisplatin with Cyclophosphamide-cisplatin[J].Eur J Cancer2003,39(81):ll29-1140
[77]Joly F,Heron JF,Kerbrat P,et al.High-dose platinum versus startdard dose in advanced ovarian carcinoma:a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers(FNCLCC) [J].Gynecol Oncol,2000,78(3 pt1):361-368.
[78] Hakes TB, Chalas E, Hoskins WJ, et a1.Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma [J].Gynecol Oncol 1992;45:284–289.
[79]Bertelsen K, Jakobsen A, Stroyer J, et a1. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide,adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Cancer Group Study [J].Gynecol Oncol,1993,49:30–36.
[80] Lambert HE, Rustin GJSD, Gregory WM, et a1.A randomized trial of five vesus eight courses of cisplain or carboplatin in advanced epithelial ovarian cancer [J].Ann Oncol 1997,8:327–333.
[81] Rosenberg PA,Andersson HA,Boman KA,et al.Randomized trial of single-agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum [J].Acta Oncol 2002, 41(5):418-424.
[82] Watanabe Y,Nakai H,Ueda H,et a1.Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer [J].Gynecol Oncol,2005,96(2):323-329
[83]Bolis GA,F avalli GA, Danese SA et al.weekly cisplatin given for 2 moths versus cisplatin plus cyclophamidegiven for 5moths after cytoreductive surgery for advance dovarian cancer [J].J Clin Oncol, 1997,15(5):1938-1944.
[84]Cocconi GA, Bella MA, Lottici RA, et al. Mature results of prospective randomized trial comparing a three-weekly with an acceleeated weekly schedule of cisplatin in advance ovarian carcinoma [J].Am J Clin Oncol, 1999, 22(6):559-567
[85]李彩云,张才兴,高雪梅等.卵巢癌术后腹腔温热灌注联合化疗疗效观察[J].人民军医,2007,50(2):87-89
[86]夏宗懿,戴志远.晚期卵巢癌预后影响因素分析[J].苏州医学.2003,26(2):73-74
[87]连利娟等.林巧稚妇科肿瘤学.北京,人民卫生出版社,2001,p585.
[88]唐勇,李力,唐兆前等.卵巢上皮癌术后化疗期间血清CA125检测与其预后关系的研究[J].中国癌症防治杂志.2009,1(1):36-38.
[89]Nakayama K, Takebayashi Y, Nakayama S, et al.Prognostic value of over expression of P53 in human ovarian carcinoma patients receiving ciplatin [J].Cancer Lett, 2003, 192:227-235.
[90]王绍娟,魏萍,李家梅等.卵巢癌基因表达与化疗疗效及预后相关性的研究[J].临床和实验医学杂志,2006,5,(10):1548-1549.
[91]傅士龙,张国玲,李子庭等.卵巢癌p53、MDR1、GST-π基因的共表达与化疗疗效的相关性[J].世界肿瘤杂志.2002,l(2):99-102.
[92]魏风华,赵晓东,张毅.铂类联合紫杉醇对晚期卵巢癌一线化疗疗效预测因素的研究[J].中华医学杂志.2007(87)l7:1187-1189.
[93] Sui L, Dong Y, Ohno M , et al. Inverse expression of cdk4 and p16 in epithelial ovarian tumours [J].Gynecol Oncol, 2000, 79(2):230-237.
[94]Masciullo V, Ferrandina G, Pucci B,et al. P27kipl expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariated analysis [J].Clin Cancer Res, 2000, 6(12):4816-4822.
[95] Sui L, Tokucla M, Ohno M, et al.The concurrent expression of P27kipl and cyclinD1 in epithelial ovarian tuours [J].Gynecol Oncol, 1999, 73(2):202-209.
[96]邹劲林,刘富元.卵巢上皮癌P27和Bcl-2表达及其意义[J].肿瘤学杂志, 2004, 10(5)302-304.
[97]Schuyer M, Van der Burg MEL, Henzen-Logmans SC, et al.Reduced expression of BAX is associated with epithelial ovarian cancer: a multifactorial analysis of TP53、P21、BAX AND Bcl-2 [J].Br Cancer, 2001, 85(9I:1359-1367.
[98]Lohmann CM, League AA, Clark WS, et al. Bcl-2:bax and bcl-2: bcl-x ratios by image cytometric quantitation of immunothemical expression in ovarian carcinoma correlation with prognosis [J].Gytometry.2000, 42(1):61-66.
[99]刘颖晖,刘宝宜,宋和存等.卵巢上皮癌中nm23基因蛋白的表达及其意义[J].中国医科大学学报, 2001,30(2):114-116.
[100] Paley PJ, Staskus KA, Gebhard K, et al.Vascular endothelial growth factor expression in early stage ovarian carcinoma [J].Cancer, 1997, 80(1):98-106.
[101] Yokoyama Y,Charnock-Jones DS, Licence D, et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma [J].Br J Cancer,2003, 88:237-244.
[102]李力,王丽梅,张玮等.卵巢恶性肿瘤患者测定血清血管内皮生长因子的临床价值[J].中华妇产科杂志, 2003, 38(2):72-76.
[103]徐军,张国玲,赵明等.血清VEGF表达与卵巢癌患者化疗疗效相关性的初步研究肿瘤[J].2000,20(2):114-115.
[104]Ferrandina G,lauriola L,zannoni G F,et al.Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and outcome in ovarian cancer patients [J].Ann Oncol,2002, 13(8):l205-l2l1.
[105] Raspollini MR,amunni G,villanucci A,et al.Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170(MDR1) expression is associated with chemotherapy resistance andpoor prognosis:analysis in ovarian carcinoma patients with low and high survival [J].Int J Gyn Cancer,2005,15(2):255-260.
[106]潘珊,吴绪峰,陈惠祯.上皮性卵巢癌组织中环氧化醇2的表达与化疗耐药及预后的相关性研究[J].肿瘤,2007, 27(1):46-50.
[107] Ostanin AA, Chernykh HR, Leplina OY, IL-2-Activated Killer Cells and Native Cytokines in Treatment of Patients with Advanced Cancer.Russ J Immunol, 1997 ,2(3-4):167-176.
[108] Lum LG,Lefever AV,Treisman JS,et al.Immune Modulation in Cancer Patients After Adoptive Transfer of Anti-CD3/Anti-CD28-Costimulated T Cells-Phase I Clinical Trial.J Immunother, 2001 ,24(5):408-419.
[109]Marme A, Strauss G, Bastert G,et al. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma.Int J Cancer, 2002 ,101(2):183-189.
[110] Melichar B, Savary CA, Patenia R, et al. Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma.Int J Gynecol Cancer, 2003 ,13(4):435-443.
[111]Berek JS,Stonebraker B,Lentz SS,et al.Intraperitoneal alpha-interferon in residual ovarian carcinoma:a phase II gynecologic oncology group study .Gynecol Oncol,1999,75:10-14.
[112] Santin AD,Ioli GR,Hiserodt JC,et al.Development and characterization of an IL-4-secreting human ovarian carcinoma cell line. Gynecol Oncol,1995,58(2):230-239.
[113] D'Incan C, Sanches R, Kuiper M, et al. Gamma-interferon gene transfer as a therapeutic strategy for ovarian cancer[J].Adv Exp Med Biol,1998,451:349-52.
[114]Bernhard H, Salazar L, Schiffman K,et al. Vaccination against the HER-2/neu oncogenic protein.Endocr Relat Cancer, 2002,9(1):33-44.
[115]Linehan DC, Peoples GE, Hess DT, et al.In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour. Surg Oncol, 1995,4:41-49.
[116]Brossart P. Dendritic cells in vaccination therapies of malignant diseases.Transfus Apheresis Sci, 2002 ,27(2):183-186.
[117]Reinartz S,Boerner H,Koehler S,et al.Evaluation of immunological responses in patients with ovarian cancer the anti-idiotype vaccine ACA125 by determination of intracellular cytokines-a preliminary report .Hybridom,1999,18:41-45.
[118]Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ,et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.Oncogene, 2003 ,22(3):370-380.
[119]Grove JI, Lovering AL, Guise C,et al. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.Cancer Res, 2003,63(17):5532-5537.
[120]Alvarez RD, Barnes MN, Gomez-Navarro J,et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.Clin Cancer Res, 2000,6(8):3081-3087.
[121]Wen SF, Mahavni V, Quijano E,et al. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer.Cancer Gene Ther, 2003 ,10(3):224-238.
[122]Buller RE, Runnebaum IB, Karlan BY, et al.A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.Cancer Gene Ther,2002,9(7):553-566.
[123]Saga Y, Mizukami H, Takei Y,et al. Suppression of cell migration in ovarian cancer cells mediated by PTEN overexpression.Int J Oncol, 2003 ,23(4):1109-1113.
[124]Qian GZ, Cao SJ,et al. The experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN-gamma genes.Int J Gynecol Cancer, 2002 ,12(1):80-85.
[125]Qian AJ, Kuhlcke K,et al. Multidrug resistance 1 gene transfer can confer chemoprotection to human peripheral blood progenitor cells engrafted in immunodeficient mice.Hum Gene Ther, 2002 ,13(2):233-242.
[126]Takahashi S, Hatake K, Sugimoto Y. Gene therapy for breast cancer.Gan To Kagaku Ryoho, 2003 ,30(4):468-477.
[127] Kohno T, Mizukami H, Suzuki M,et al. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer.Cancer Res, 2003 ,63(16):5091-5094.
[128] Mu J, Abe Y, Tsutsui T,et al. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.Jpn J Cancer Res, 1996 ,87(9):963-971.
[129]Han xiaohong,Gai xiaodong,Xue yanjian.On cancer multidrugresistance reversal [J].Journal of Bei Hua University ( NationalScience),2005,6(1):36-37.
[130]Zhou Jun,Liu Min,Luthra R,et al.EM012,a microtubule-interfering agent,inhibits the progression of multidrug resistant human ovarian cancer both in cultured cells and in athymic nude mice [J].Cancer Chemother Pharmacol,2005,55(5):461-465.
[131]卢丹,王志学.卵巢癌组织中多药耐药基因蛋白表达及其临床价值[J].肿瘤防治杂志,2004,11(5):512-514.
[132]熊丽丽,田晓予.PKCα、PKCε及P-gp在卵巢癌中的表达及其临床意义[J].广东医学2006;27(7):1026-1028.
[133] Hille S,Rein DT,Riffelmann M,et al.Anti-cancer drugs induce mdr1 gene expression in recurrent ovarian cancer [J]. Anticancer Drugs.2006,17(9):1041-1044.
[134] Cole SP,Deeley RG.Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP [J].Bioessays,1998,20(11):931-940.
[135] Laochariyakul P,Ponglikimongkol M,Mankhetkom S,Functional study of in tracellular P-gp and MRP-1 mediated pumping of free cytosolic pirarubic in into acidic organe cells in intrinsic resistant Siha cells [J].Can J Physiol Phamaco.2003,81(8):790-799.
[136]张树荣.卵巢癌组织中MDR1、survivin、topoII的表达及临床意义[J].中国妇幼健康研究,2006,17(6):564-465.
[137] Yakirevich E,Sabo E,Naroditsky I,et al. Multidrug resistance related phenotype and apoptosis-related protein expression in ovarian serous carcinomas [J].Gynecol Oncol,2006,100 (1):152-159.
[138] Wang W,Ke S,Chen G.Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines [J].Oncol Rep,2004,12(6):1365-1367
[139] Larsen AK,Escargueil AE,Skladanowski A.Resisance mechanisms associated with altered intracellular distribution of anticancer agent [J].Pharmacol Ther, 2000,85(3):217-229.
[140] Jia P,Wu S,Li F, et al.Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells [J].Int J Gynecol Cancer. 2005,15(6):1042-1048.
[141]Nagle CM,Chenevix-Trench G,Spurdle AB,et al.The role of glutathione-S-transferase polymorphisms in ovarian cancer survival [J].Eur J Cancer. 2007,43(2):283-290
[142]Morari EC,Lima AB,Bufalo NE. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients [J]. J Cancer Res Clin Oncol, 2006, 132 (8):521-528.
[143]Selvakumaraa M ,Pisarcik DA,Bao R.Enhanced cisplatin cytotoxicity by disturbing thenucleotide excision repair pathway in ovarian cancer cell lines [J].Cancer Ras, 2003, 63(6),1311-1316.
[144] Helleman J,van Staveren IL,Dinjens WN,et al.Mismatch repair and treatment resistance in ovarian cancer [J].BMC Cancer,2006,6:201-210.
[145] Duan Z, Duan Y, Lamendola DE, et al. Overexp ression of MAGE /GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines [J].Clin Cancer Res, 2003, 9 (7): 2778-2785.
[146] Kennedy RD, Quinn JE, Mullan PB, et al.The role of BRCA1 in the cellular response to chemotherapy [J].J Natl Cancer Inst.2004,96(22):1659-1668.。
[147]Yang X, Zheng F,Xing H,et al.Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and 0verexpression of anti-apoptotic proteins in ovarian cancer [J].J Cancer Ras Clin Oncol,2004,130(7):423-428
[148] Abedini M R,Qiu Q ,Yan X,et al.Possible role of FLICE-like inhibitory protein(FLIP)in chemoresistant ovarian cancer ceils in vitro [J].Oncogene,2004,23(42):6997-7004
[149]Yang X,Xing H,Gao Q,et al.Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells [J].Gynecol Oncol, 2005, 97(2):413-421
[150] Gadducci A ,Cosio S,M uraca S,et al.Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer:Biological data and clinical implications [J].Eur J Gynaecol Oncol,2002,23(5):390-396.
[151] 116.Skirnisdottir I, Seidal T , Gerdin E,et al.The prognostic importance of p53,bcl-2,and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy [J].Int J Gyneeol Cancer,2002,12(3):265-276.
[152] Lee S,Choi EJ,Jin C,et al.Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line [J].Gynecol Oneol,2005,97(1):26-34.
[153]夏婷.卵巢癌中PKC和P-gp的表达极其临床意义[J].肿瘤防治研,2005,32(3):152-154.
[154]Ateller MD,Shaw TJ,Vanderhyden BC,et al.Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells [J].Mol Cancer Res,2005,3(1):50-61.
[155] ParkSJ,Armstrong S,Kim CH,et al.Lack of ecg receptor contributes tu drug sensitibity of human germline cells [J].Br J Cancer,2005,92(2):334-341.
[156]Abuharberk S,Apel J,Zugmaier G,et al.Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV3 ovarian carcinoma cells [J]. Naunyn Schmiedebergs Arch Pharmacol,2005,371(2):141-151.
[157]RangelLB,Agarwal1R,D.SouzaT,etal. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas [J]. Int J Clin Cancer Res, 2003,9:2567-2575.
[158] Santin AD,CanS,BelloneS,et al. Treatment of chemotherapy-resistant human ovarian cancer xenografts in CB-17/SCID mice by intraperitoneal administration of clostridium perfringens enterotoxin [J].Cancer Res,2005,65(10):43340-4342.
[159] Katano K,Safaei R,Samimi G,et al.The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells[J].Mol Pharmacol,2003,6(2)4:466-473.
[160] Nakayama K,Kanzaki A,Ogowa K,et al.Copper-transporting p-type adenosine triphosphatase(ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma:comparative analysis with expression of MDR1,MRP1,MRP2,LRP and BCRP[J].Int J Cancer,2002,101(5):488-495.
[161]Sudo T, Nitta M, Saya H,et al.Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint [J].Cancer Res,2004,64(7):2502-2508。
[162]梁川,吴绪峰,陈慧君.卵巢癌中MDR1的表达及其临床意义[J].肿瘤防治研究.2008.35(10): 723-726.
[163]张素娟,闫洪超,薛加强.MDR1基因在上皮性卵巢癌组织中的表达及临床意义[J].实用诊断与治疗杂志.2007,21(7):515-516.
[164] Kolfschoten GM,Hulscher TM,Pinedo HM,et al.Drug resistancefeatures and S-phase fraction as possible determinants for drug responsein a panel of human ovarian cancer xenografts [J] .Br J Cancer,2000,83(7):921-927.
[165]Brinkhuis M,Izquierdo MA,Baak JP,et al.Expression of multidrug resis tance-associated markers,their relation to quantitative pathologic tumour cha- racterristics and prognosis in advanced ovarian cancer [J]. Anal Cell Pathol.2002,24(1):17-23.
[166] Beeghly A,Katsaros D,Chen H,et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival [J].Gynecol Oncol. 2006,100(2):330-337.
[167] Watanabe Y, Ueda H, Etoh T, etal A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer[J].Anticancer Res, 2007, 27(3B): 1449-1452.
[168]Strathdee G, MacKean MJ, Illand M, et al .A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer[J]. Oncogene. 1999 ,18(14):2335-2341.
[169]Obata H,Yahata T,Quan J,et al Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer [J].Anticancer Res,2006,26 (3B):2227-2232.
[170]WilliiamsJ,Lucas PC,Griffith KA,et al.Expression of BCL-XL in ovarian carcinoma is associated with chemoresistance and recurrent disease [J]. GynecolOncol, 2005, 96 (2):287-295.
[171]Spentzos D, Levine DA, Kolia S,et al.Unique gene expression profile based on pathologic response in epithelial ovarian cancer[J]. J Clin Oncol. 2005,23(31):7911-7918.
[172]Spentzos D, Cannistra SA, Grall F, et al.IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer[J]. Endocr Relat Cancer. 2007 ,14(3):781-790.
[173]Hartmann LC, Lu KH, Linette GP, et al.Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy[J]. Clin Cancer Res. 2005,11(6):2149-2155.
[174]Protopapas A, Diakomanolis E, Bamias A, et al.Michalas SThe prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D inovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy[J]. Eur J Gynaecol Oncol. 2004;25(2):225-229.
[175]Cannistra S.Is there a best choice of second-line agent in the treatment of recurrent ,potentially platinum-sensitive ovarian cancer [J] ClinOncol, 2002, 20(5): 1158-1160.
[175]孙红,张惜阴,丰有吉.重组白细胞介素2联合化疗治疗卵巢癌复发和转移灶的探讨[J] .中国肿瘤生物治疗杂志.1 9 9 9,6 ( 4 ) :312-313.
[176]林宏伟,栗敏,刘晶。奥沙利铂联合吉西他滨治疗难治性卵巢癌临床观察[J].山东医药2 0 0 9年第4 9(3 2):86-87.
[177] Breidenbach M, Rein DT, Mallmann Peter, et al.Individualized long-term chemotherapyfor recurrent ovarian cancer after failing high-dose treatment [J].Anti-CancerDrugs, 2 0 02;13(2):173-176.
[178] Dizon DS,Dupont J,Anderson S,et al.Treatment of recurrent ovarian cancer:a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel:The Memorial SloanKettering Cancer Center experience [J].Gynecol Oncol,2003,91(3):584-590.
[179]Eisenhauer EA,Ten Bokkel Huhmlk W ,wcncrton KD,et a1.European-Canadian ran domized uial of paclitaxel in re1apsed ovarian cancer: high-dose versus low-dose and long versus short infusion [J].J Clin Onco1.1994.12 f12):2654-2666.
[180] Sugiyama T, Yakushiji M, Nishida T, et a1. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer[J]. Cancer Lett. 1998 Jun 19;128(2):211-218.
[181] FenneHy D, Aghajanjan C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administrated weekly in patients with relapsed ovarian cancer [J].J Clin Oncol,1997,15(1):187-192
[182]Rose PG,Fusco N,Fluelen L,et al.Second-line therapy with paclitaxel and carboplatin for recurent disease following first-line therapy with paclitaxel and platinum in ovarianor peritoneal carcinoma [J].Clin Oncol,1998,16(4):1494-1497
[183]ParmarMK,Ledermann JA,Colombo N,et al.Paclitaxel plus platinum-based chemotherapy versus conventionalPlatinum-based chemotherapy in women withrelapsed ovarian cancer:the ICON4/AGO-OVAR-2.2 trial [J].Lancet,2003,361(9375):2094-2095.
[184] Du Bios A,Luck HJ,Pifsterer J,et al.Sencond-line carboplatin and gemcitabine in platinum sensitive ovarian cancer-a dose finding study by the AGO ovarian cancer study group [J].Ann Oncol,2001,12(8):1115-1112.
[185] Kose MF, Sufliarsky J, Beslija S, et al. A pIlase II study of gemeitabine plus carboplatin in platinum-sensitive,recurrent ovarian carcinoma [J].Gynecol Oneal ,2005,96(2):323-329.
[186]Covens A,Blessing J,Bender D,et al.A phase 1I evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer:A Gynecologic Oncology Group study [J].Gynecol Oneul,2006,100(3):586-590.
[187] M eyer T, Nelstrop AE,Mahmoudi M ,et al.Weekly cisplatin an doral etoposide as treatm ent for relapsed epithelial ovarian cancer [J].Ann Oncol,2001,12(12):1705-1709
[188] Morgan RJ Jr,Braly P,Leong L,et al.Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer:long-term follow-up [J].Gynecol Oncol,2000,77(3):433-438.
[189] Sundar S,Symonds RP,Decatris MP,et al.Phase II trial of Oxali platin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum based therapy [J].Gynecol Oncol,2004,94:502-508.
[190]McGuire wP,Blessing JA,Bookman MA,et al.Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma :a GOG study [J].J Clin Oncol,2000,18(5):1062-1067.
[191]Gordon AN,Fleagle5r,Guthrie D,et al.Recurent epithelial ovarian carcinoma randomized phase Ill study of pegylated liposomal doxorubicin versus topotecan [J].J Clin Onco l,2001,19(141):3312-3322.
[192] Markman M ,Iseminger KA,Hatch KD,et al.Tamoxifen in platinum -refractory ovarian cancer:a GOG an cillary report [J].Gyneco1 Oncol,1996,62:4-6
[193] Benedetti Panici P,Greggi S,Amoroso M,et al.A combination of platinum and tamoxifen in advan ced ovarian cancer failing platinum-based chemotherapy: results of a PhaseⅡstudy [J].Int J Gynecol Cancer, 2001,11(6):438-444
[194] Haniani P,Nolte S,Shahin MS,et al.Phase lI evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer [J].Gynecol Onco l,2002,85(2):278-284.
[195] Gore M,Huinink WB,Carmichael J,et al.Clinical evidence for topotecan -paclitaxel non-cross-resistance in ovarian cancer [J].Clin Oncol,2001,19(7):1893-1900.
[196]Markmean M .Intraperitoneal therapy of ovarian cancer [J].Semin Oncol, 1998, 25 (3):356-360.
[197] Legros M,Dqulplat J,Heury J,et a1 High-dose chemonthrapy with hematopoietic rescue in patients with stage III to IV ovarian cancer:long-term results [J].J Clin Oncol,1997, 15(4):1302-1308.
[198] Nahhas W A.Ovarian cancer:Curent outlook on the deadly disease[J].Postgrad Med, 1997,102(3):112-120.
[199] Markman M ,Kennedy A,Sutton G,et al.Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent [J].Gynecol Oncol,1998,70(2):272-274.
[200] Nahhas W A.Ovarian cancer:Curent outlook on the deadly disease[J].Postgrad Med, 1997,102(3):112-120.
[201]Piccart MJ,GreenJA,Lacave AJ,et al.Oxaliplatin or paclitaxel in patients with plaunum -pretreated advan ced ovarian cancer:a randomized phase lI study of the European organization for research and treatment of Cancer Gynecology Group [J].J Clin Oncol,2000,18(6):1193-1202.
[202]Gareia AA,O’Meara A,Bahador A,et al.Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer [J].Gynecol Oncol,2004,93 (2):493 -498.
[203]Bookm an MA,M almstrom H,Bolis G,et al.Topotecan for the treatment of advanced epithelial ovarian cancer:an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel [J].J Clin Oncol,1998,16(10):3345-3335.
[204] Gershenson DM,Burke TW,Morris M,et al. A phase I study of a daily X3 schedule of intrax enous vinorelbine of refractory epithelial ovarian cancer [J].GynecolOncol,1998,70(3):404-409.
[205]Marklilan M.Second-1ine treatment of ovarian cancer with single-agent gemcitabine [J].Semin Onco1,2002,29(1):9-10.
[206]Aravantinos G,Bafaloukos D,Fountzilas G,et al.Phase II study of docetaxel-vinorolhine in platinum-resistant,paelitaxel-pretreated ovarian cancer [J].Ann Oncol, 2003, 14(7) :1094-1099.
[207]Cohn DE,Valmadre S,Resnick KE,et al.Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer [J].Gynecol Oncol,2006,1 02(2):134- 139.
[208]Raspagliesi F, Zanaboni F, Vecchione F,et al.Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane[J]. Oncology, 2004,67(5-6):376-81.
[209]du BA,Meier W,Luck HJ,et al.Chemotherapy versus hormonal treatment in platinum-and paclitaxel-refractory ovarian cancer:a randomized trial of the German AGO study group ovarian cancer [J].Aim Oncol,2002,13(2):251-257.
[210] Penson RT,SupkoJG,Seiden MV,et al.A phase I- II study of 96-hour infusional topotecaB and paclitaxel for padents with recurrent mullerian tumors [J]. Cancer, 2001,92(5):l156-l167.
[211]Fleming GF,Waggoner SE,Rotmensch J.et al.Absence of major peripheral neuropathy in a phaseⅡtrial ofifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel [J].AmJ Clin Onco1,2001,24(1):52-57.
[212]Gordon AN, Fleagle JT, Guthrie D, et al.Recurent epithelial ovarian carcinoma randomized phase III study of pegylated liposomal doxorubicin versus topotecan [J].J Clin Onco l,2001,19(141):3312-3322.
[213]Petru E, Angleitner-Boubenizek L, Reinthaller A, et al. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study[J]. Gynecol Oncol. 2006 Aug;102(2):226-229.
[214]Thigpen T .The role of gemcitabine-based doublets in the management of ovarian carcinoma [J].Semin Oncol,2002,29(1):l1-l6.
[215] Rose PG, Rodriguez M, Walker J,et al.A phase 1 trial of prolonged oral etoposide and liposomal doxorubicin in ovarian peritonea1 and tubal carcillonla:a GOG study[J]. Gynecol Onco1,2002,85:136-l39.
[216]Rocereto TI,Sanl HM.AikiI1s IA.et al.PhaseⅡstudy of mifepristone(RU486)in refractory ovarian cancer [J].Gynecol On.co1,2000,77(3):429-432.
[217]Gore ME, Atkinson RJ, Thomas H, et al. Results of ZD0473 in platinum- pretreated ovarian cancer:analysis according to platinum free interval [J].Eur J Cancer, 2002, 38(Suppl 8):S7-12.
[218] Blackledge G.Cancer drugs:the next 10 years [J].Eur J Cancer, 2003, 39(3):273.
[219] Gronlund B, Hogdall C, Hansen HH, et al.Performance status rather than age is the key prognostic factor in second2line treatment of elderly patients with epithelial ovarian carcinoma [J].Cancer, 2002, 94(7):1961-1967.
[220]Molitemi A,Menard S,Valagussa P,et al.HER2 overexpression and doxorubiein in adjuvant chemotherapy for respectable breast cancer [J].J Clin Oncol,2003,21:458-462.
[221]赵晓东,张毅,何淑蓉等.P53表达对晚期上皮性卵巢癌一线化疗方案选择的意义[J].癌症.2005,24(12):1542-1554.
[222]赵晓东,张毅等,复发卵巢上皮癌“常规化疗药物疗效预测分子靶向化疗”的初步探讨[J].现代妇产科进展,2006;15(4):265-267.
[223]Zhao XD, Wei FH, Zhang Y, et al.Treatment of platinum-resistant recurrent ovarian cancer using a "predictive molecule targeted routine chemotherapy" system[J]. Chin Med J (Engl). 2009 ,122(23):2856-2860.
[224] Omura GA,Brady MF,Look KY,et al.Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study [J].J Clin Oncol. 2003,21(15):2843-2848.
[225]Vasey PA,Atkinson R,Coleman R,et al.Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer [J].Br J Cancer. 2001 Jan;84(2):170-178.
[226] Ledermann JA,Herd R,Maraninchi D,et al.High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT) [J].Ann Oncol.2001,12(5):693-699.
[227]Nieboer P,de Vries EG,Mulder NH,et al.Long-term haematological recovery following high-dose chemotherapy with autologous bone marrow transplantation or peripheral stem cell transplantation in patients with solid tumours [J].Bone Marrow Transplant. Bone.2001,27(9):959-966.
[228]林元藻.反义核酸的研究及应用[J].广东药学院学报,2000,16(1):48
[229]Tong Y,Pan L,Zhou S.Study of mdr1 antisense oligodeoxynucleotides on renersal of multidrug resistance in ovarian carcinoma cell line SKOV3 [J] .Zhonghua Fu chan Ke Za Zhi,2003,35(11):677-679.
[230]TouboulM,Gauchez AS,D Hardemare A du M,et al. Early detection of chemoresistance in vivo through the use of a radiolabeled antisense oligonucleotide [J].Anticancer Res,2002,22(6A):3349-3356.
[231]Masanek U,Stammler G,Volm M.Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of p-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides [J].ExpThher Oncol,2002,2(1):37-41.
[232]Zhang T,Guan M,et al. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells [J].Gynecol Oncol. 2005,97(2):501-507.
[233] Wu H,Hait WN,Yang JM,et al.Small Interfering RNA induced Suppres- sion of MDR1(P-Glycoprotein) Restores Sensitivity to Multidrug resistant Cancer Cells [J].Cancer Res,2003,63(4):1515-1519.
[234]张晓菁,温泽清,张华玲,等.小干扰RNA抑制多药耐药基因表达并逆转耐药[J].中国实用妇科与产科杂志.2006,22(1):29-31.
[235]Kobayashi H,Takermura Y,Wang FS,et al.Retrovirus-mediated transfer of anti-MDR-1 hammerhead ribozymes into multidrug-resistant human leukemia cells:screening of effective target sites [J].Cancer,1999,81;944-950.
[236]Nagata J,Kijima H,Hatanaka H,et al.Reversal of drug resistance usinghammerhead ribozymes against multidrug resistanceassociated protein and multidurg resistance 1 gene[J].Oncol,2002,2195:1021-1026.
[237]杨晓葵,邢辉,高庆蕾,等.mdr-1特异性核酶逆转卵巢癌的多药耐药[J].中华肿瘤杂志,2003,25(5):425-427.
[238]Wen SF,Mahavni V,Quijano E,et al.Assessment of p53 gene transfer and biological activities in a clinical study of ademovires-p53 gene thetapy for recurrent ovarian cancer [J].Cancer Gene Thet.2003,10(3):224-238.
[239]Vasey PA,Shulman LN,CamposS,et al.Phas I trial ofin traperitoneal in jiection of the E1B-55-kd gene deleted adeno virus ONYX-015,given on days 1 through 5 every 3 weeks in patients with recurren/refratory epithelial ovarian cancer[J].Cline Oncol.2002.20(6):1562-1569.
[240]Bentires A IjM,Barbu V,Fillet M,et al.NF-kappa B transcription factor induces drug resistance through MDR1 expression in cancer cells [J].Oncogene ,2003,22(1):90-97.
[241]戴春岭,符立梧.肿瘤MDR逆转剂的研究进展[J].中国药理学通报,2005,21 (5):513-518.
[242]Francois H,Catherine V,Pierre DV,et al.In vitro and in vivoreversal of multidrug resistance by GF120918,an acridonecarboxamide derivative[J].Cancer Res,1993,53(19): 4595-4602.
[243] Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies [J]. Blood, 2004,104(7):1940-51.
[244]Ludwig JA,Szakacs G,Martin SE,et al.Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer [J].Cancer Res.2006,66(9):4808-4815.
[245] Zhou J, Liu M, Aneja R,et al.Reversal of P-glycoprotein-MediatedMultidrug Resistance in Cancer Cells by the c-Jun NH2-Terminal Kinase[J].Cancer Research,2006,66(1):445-52.
[246] Zhang L, Yang Y, Wei XY, et al. Reversing adriamycin resistance of human breast cancer cells by hyperthermia combined with Interferon alpha and Verapamil[J].J Exp Clin Cancer Res,2007 ,26(2):201-207.
[247]Lewandowicz GM,Britt P,Elgie AW,et al.Cellular glutathione content in vitro chemoresponse and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer [J].Gyneco Onceol,2002,85(2);298-304.
[248]Fojo T, Bates S.Strategies for reversing drug resistance [J].Oncogene,2003,22:7512-7523.
[249]Rosario LA, O'Brien ML, Henderson CJ, et al.Cellular response to a glutathione S-transferase P1-1 activated prodrug[J]. Mol Pharmacol, 2000 ,58(1):167-174.
[250]Townsend DM,Shen H,Staros AL,et al. Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells[J].Mol Cancer Ther,2002,1(12):1089-1095.
[251]Versantyoortc HM,Schuurhuis GJ,Pinedo HM,et al.Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells [J].Br J Cancer,1993,68:939-946.
[252] Allen JD, van Loevezijn A, Lakhai JM,et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. [J].Mol Cancer Ther, 2002,1(6): 417-425.
[253]Yasuo Imai,Satomi Tsukahara,Sakiyo Asada,et al. Phytoestrogens /Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2 Mediated Multidrug Resistance [J].Cancer Research,2004,64(12):434-611.
[254]崔恒.卵巢癌的治疗策略[J].继续医学教育.2006,20(8):79-84.
[255]Peter GR.Surgery for recurrent ovarian cancer [J].Semin in Oncol,2000, 27:17-23.
[256] Gungor M,Ortac F,Arvas M,et al.The role of secondary cytoreductive surgery for recurrent ovarian cancer [J].Gynecol Oncol,2005,97(1):74-79.
[257]Hassenburg A,Tong XW,fischer DC,et al. A denovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer 2.5–year follow-up [J].Gynecol Oncol,2002,83(3);549-554.
[258] Deshane J,Cabrera G,Grim JE,et al.Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erB-2 singlechain antibody [J].Gynecol Oncol, 1995, 59:8-11.
[259]Cannon MJ,O Brien TJ,Underwood LJ,et al.Novel targe antigens for dendriteic sell-based immunothetapy against ovarian cancer [J].Expert Rev Anticancer Ther,2002,2(1):97-105.
[260] Hesdorffer C,Ayello J,Ward M,et al.Phase I trial of retrobiral mediated transfer of thehuman MDR1 genes as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell reansplantation [J].Clin Oncol, 1998, 16(1):165-172.
[261] Binyamin L,Assaraf YG,Haus-Cohen M,et al. Targeting an extracel- lular epitope of the human multidrug resistance protein 1 (MRP1) in malignant cells with a novel recombinant single chain Fv antibody [J]. Int J Cancer.2004,110(6):882-890.
[262] Mc Quarrie SA,Mercer JR,Syme A,et al.Preliminary results of nanophaimaceutikal used in the radio immunotherapy of ovarian cancer [J].J Phaim Phaimaceut Sci,2004, 7(4): 29-34.
[263]Wang Z,Cai L,Wang H. Gene therapy of adenovirus mediated CD::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer [J].Gynecol Oncol, 2005, 96(3):643-650.
[264] Boumendjel A,Baubchon Cortay D.Anticancer multidrugresistance medi- ated by MRP1:recent advances in the discovery of re2versal agents [J].Med Res Rev, 2005,25(4):453-472.
[265]韩晓红.肿瘤细胞多药耐药逆转研究[J].北华大学学报(自然科学版),2005,2(6):36-42.
[266]立彦.P-gp介导的肿瘤多药耐药逆转研究进展[J].放射免疫学杂志,2005,18(2):133
[267]李大成,屈艺,刘柏林,等.三种中药制剂Ams-11,Fw-13,Tul-17逆转肿瘤细胞多药耐药性的研究[J].华西医科大学学报,1998,29(1):16.
[268]贾莉,孔力,苗小艳,等.蝎毒逆转K562/ADM细胞多药耐药性的初步研究[J].白血病淋巴瘤,2002,11(2):81-83.
[269]杨孝军,郑飞云,陈必成,等.亚致死量陡脉冲调节人卵巢癌细胞多药耐药的实验研究[J].中华物理医学与康复杂志,2005,27(10):597-560.
[270]白符,冯捷.基因芯片技术在卵巢癌相关基因研究中的应用[J].中国妇产科临床杂志,2004,5(2):157-159.
[271]Kothapalli R,Yoder SJ,Mane S,et al.Microarray results:how accurate are they? [J].BMC Bioinformatics,2002,23(3):22.
[272]胡恭华. DDRT-PCR技术及其在毒理学研究中的应用[J].毒理学杂志,2005, 19(3): 232-235.
[273] Liang P,Pardee AB.Distribution and cloning of eukaryotic mRNAs by means of differential display:refinementsand optimization [J].Nucleic Acids Res,1993,21:3269-3275
[274]王新,兰梅等,不同mRNA差异显示法筛选为癌细胞耐药相关基因的研究[J].肿瘤防治研究.2002,29(3),177-180.
[275] Ylstra B,van den Ijssel P,Carvalho B,et al.BAC to the future or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH) [J]. NucleicAcids Res,2006,34(2):445-450.
[276]彭翼飞,马文丽.寡核苷酸阵列比较基因组杂交技术及其应用[J].中国生物工程杂志,2006,26(10):46-51.
[277]梁丽,丁彦青,石益民.消减抑制杂交及其在肿瘤中的应用[J].癌症.2003,22:997-1000.
[278]罗洁,许辉.基因差异表达分析技术及其在糖尿病研究中的应用[J].实用预防医学, 2005,12(6):1482-1485.
[279] Zhao ZL,Huang X,LiN,et al. Direct cloning of cell differential expression genes with full-length by a new strategy based on the multiple rounds of“long distance”polymerase chain reaction and magnetic beads mediated subtradion [J].J Biotechno1, 1999, 73(1) : 35-4l.
[280] L'Espérance S, Popa I, Bachvarova M,et al.Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors[J]. Int J Oncol. 2006 ,29(1):5-24.
[281]Goto T, Takano M, Sakamoto M,et al.Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers [J].Oncol Rep,2006,15(5):1265-1271.
[282] Li J, Wood WH 3rd, Becker KG,et al.Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells [J].Oncogene,2007,26(20):2860-2872.
[283] Roberts D,Schick J,et al. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells [J].Cancer.2005,92(6):1149-1158.
[284]Varmapr,Hector SM,et al. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10 [J].Oncol Rep, 2005, 14(4):925-932.
[285]Olivero M, Ruggiero T,Saviozzi S,et al.Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin [J].Mol Cancer Ther, 2006, 5(5): 1126-1135.
[286]Komatsu M, Hiyama K, Tanimoto K, et al. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers [J]. Mol Cancer Ther. 2006 ,5(3):767-75.
[287]Verena Materna, Pawel Surowiak,et al. TRAG-3/CSAG2 expression is associated with paclitaxel resistance in ovarian carcinoma cell lines and with clinical outcome in ovarian carcinoma patients[J]. Proc Amer Assoc Cancer Res, 2005( 46):187-194.
[288] Duan Z, Feller AJ, Toh HC, et al.TRAG23,a novel gene isolated from ataxol resistan to varian carcinoma cell line [J].Gene,1999,229(122):75-81
[289] Sigalotti L,Coral S,Altomonate M,et al.Cancer testisantigen expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implication [J].Br J Cancer, 2002,86(6):979-982.
[290]Feller AJ,Duan Z,Penson R,et al.TRAG23,a novel cancer/testisantigen,is overexpresed in the majority of melanoma cell lines and malignant melanoma [J].Anti cancer Res,2000,20(6B):41-47.
[291]Li L,Luan Y,et al. Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis [J]. Oncol Rep, 2005,13(5):793-799.
[292]田方,李春海.mRNA差异显示法筛选卵巢癌细胞株细胞耐药相关基因的初步研究[J].癌症,2000;19(8):744-747.
[293]M Bernardini, CH Lee, B Beheshti, M Prasad,et al. High-resolution mapping of genomicimbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer [J].Neoplasia,2005,7(6): 603-613.
[294]Chaib H, Cockrell EK, Rubin MA, et al.Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis[J]. Neoplasia. 2001,3(1):43-52.
[295]Kuo K C, McCune R A, Gehrke C W, et al. Quantitative reversed-phase high performance liquid chromatographic determination of major and modified deoxyribonucleosides in DNA [J]. Nucleic Acids Res, 1980, 8: 4763-4776.
[296]Fraga M F, Uriol E, Borja D L, et al. High-performance capillary electrophoretic method for the quantification of 5-methyl 2-deoxycytidine in genomic DNA: application to plant, animal and human cancer tissues [J]. Electrophoresis, 2002, 23: 1677-1681.
[297]Oefner, P J, Bonn G K, Huber C G, et al. Comparative study of capillary zone electrophoresis and high-performance liquid chromatography in the analysis of oligonucleotides and DNA. [J]. Chromatogr, 1992, 625(2): 331-3401.
[298]邓大君,邓国仁,吕有勇等.变性高效液相色谱法检测CpG岛胞嘧啶甲基化[J].中华医学杂志, 2001, 80(2), 158–1611.
[299]Wu J, Issa J, Hermen J, et al. Expression of an exogenous eukaryotic DNA methyl transferase gene induces transformation of NIN3T3 ceils [J]. Proc Natl Acad Sci USA, 1993, 90(19): 8891–8895.
[300]Oakeley E J, Podesta A, Jost J P. Developmental changes in DNA methylation of the two tobacco pollen nuclei during maturation [J]. Proc Natl Acad Sci USA, 1997, 94: 11721–11725.
[301]Oakeley E J, Schmitt F, Jost J P. Quantification of 5-methylcytosine in DNA by the chloroacetaldehyde reaction [J]. Biotechniques, 1999, 27(744):748-752.
[302]Frommer M, McDonald L E, Millar D S, et al. A genomic sequencing protocol that yields apositive display of 5-methylcytosine residues in individual DNA strands [J]. Proc Natl Acad Sci USA, 1992, 89: 1827–1831.
[303]Herman J G, Graff J R, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands [J]. Proc Natl Acad Sci USA, 1996, 93(18):9821-9826.
[304]Gonzalgo M L, Jones P A. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE) [J]. Nucleic Acids Res, 1997, 25: 2529–2531.
[305]Maekawa M, Sugano K, Kashiwabara H, et al. DNA methylation analysis using bisulfite treatment and PCR-single-strand conformation polymorphism in colorectal cancer showing microsatellite instability [J]. Biochem Biophys Res Commun, 1999, 262: 671–676.
[306]Aggerholm A, Guldberg P, Hokland M, et al. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia [J]. Cancer Res, 1999, 59: 436-441.
[307]Eads C A, Danenberg K D, Kawakami K, et al. MethyLight: a highthroughput assay to measure DNA methylation [J]. Nucleic Acids Res, 2000, 28: E32.
[308]Huang T H, Perry M R, Laux D E. Methylation profiling of CpG islands in human breast cancer cells [J]. Hum Mol Genet, 1999, 8: 459-470.
[309]Gitan R S, Shi H, Chen C M, et al. Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis [J]. Genome Res, 2002, 12: 158–164.
[310]Clement G., Benhattar J. A methylation sensitive dot blot assay (MS-DBA) for the quantitative analysis of DNA methylation in clinical samples [J]. Clin Pathol, 2005, Feb. 58(2): 155-8.
[311]Nygren A O, Ameziane N, Duarte H M, et al. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences [J]. Nucleic Acids Res, 2005, Aug 16, 33 (14): e128.
[312]Balch C, Huang TH, Brown R, etal. The epigenetics of ovarian cancer drug resistance and resensitization[J]. AmJ Obstet Gynecol ,2004, 191(5): 1552-1572.
[313]Staub J, Chien J, Pan Y, et al.Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance[J]. Oncogene,2007,26:4926-4978.
[314]Jacqueline A. Hall, Jens M. Teodoridis, etal DNA methylation of markers associated with response to chemotherapy in tumor and plasma DNA of ovarian cancer patients[J].AACR Meeting Abstracts, 2006,759-761.
[315]John S. Montgomery, Curtis Balch, Mike Mand, etal Alterations in DNA methylation patterns associated with onset of chemotherapy resistance in ovarian cancer[J].AACR Meeting Abstracts, 2006, 539-541.
[316]Robert Brown, Gillian Gifford, Jim Paul, etal.The acquisition of hMLH1 methylation in plasma DNA following chemotherapy predicts poor survival for ovarian cancer patients[J]. Meeting Abstracts, 2004; 242-246.
[317]Wiley A, Katsaros D, Chen H, etal.Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer. 2006 Jul 15;107(2):299-308.
[318]Chou JL, Su HY, Chen LY, et al.Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.Lab Invest. 2010 ,90(3):414-425.
[319]Swisher EM, Gonzalez RM, Taniguchi T, et al.Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas[J].Mol Cancer. 2009 Jul 14;8:48.
[320]Strathdee G, Vass JK, Oien KA, Siddiqui N, Curto-Garcia J, Brown R.Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy[J].Gynecol Oncol. 2005 ,97(3):898-903.
[321]Horn MP, M?der-Heinemann G, Andrey G,et al.Mutation screening of the medium-chain acyl-CoA dehydrogenase (MCAD) and the ornithine transcarbamylase (OTC) genes by multiplex PCR amplification and sequencing[J]. Clin Chem Lab Med. 2009;47(1):56-59.
[322] Jiang X, Lu C, Gao F,et al.A rapid and simple method for identifying Mycobacterium tuberculosis W-Beijing strains based on detection of a unique mutation in Rv0927c by PCR-SSCP[J]. Microbes Infect. 2009,11(3):419-423.
[323]Sorlie T, Johnsen H, Vu P, et al .Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis[J].Methods Mol Biol. 2005,291:207-216.
[324]Fodde R, Losekoot M. Mutation detection by denaturing gradient gel electrophoresis (DGGE)[J].Hum Mutat, 1994;3(2):83-94.
[325]Zhang DY, Sun TM, Zhang SZ, et al.Mutation detection of PKD2 gene in Chinese by denaturing high-performance liquid chromatograph[J].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004 ,21(3):211-214.
[326]Borresen AL.Mismatch detection using heteroduplex analysis[J].Curr Protoc Hum Genet, 2002 ,Chapter 7:Unit 7.3
[327]Palais B.Quantitative heteroduplex analysis[J]. Clin Chem,2007 ,53(6):1001-1003.
[328]Abe T, Takahashi H, Holmes MD, et al .Ribonuclease A cleavage combined with the polymerase chain reaction for detection of the Z mutation of the alpha-1-antitrypsin gene[J]. Am J Respir Cell Mol Biol. 1989,1(4):329-334.
[329]Whittock NV, Ashton GH, Mohammedi R, et al Comparative mutation detection screening of the type VII collagen gene (COL7A1) using the protein truncation test, fluorescent chemical cleavage of mismatch, and conformation sensitive gel electrophoresis[J]. J Invest Dermatol, 1999 ,113(4):673-686.
[330]Yang DY, Fushimi H, Cai SQ,et al. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and amplification refractory mutation system (ARMS) analyses of medicinally used Rheum species and their application for identification of Rhei Rhizoma. Biol Pharm Bull. 2004,27(5):661-669.
[331]Pieri Pde C, Nogueira Jde A, et al . A duplex allele-specific amplification PCR to detect SMN1 deletion[J].Genet Test Mol Biomarkers, 2009 ,13(2):205-208.
[332]Perego P, Giarola M, Righetti SC, et al . Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems[J].Cancer Res, 1996,56(3):556-562.
[333]Kawasaki M, Nakanishi Y, Kuwano K, et al . The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer [J] . Clin Cancer Res, 1997, 3(7):1195-1200.
[334]Salani R, Kurman RJ, Giuntoli R , et al.Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance[J].Int J Gynecol Cancer. 2008,18(3):487-491.
[335]Mustea A, Sehouli J, Fabjani G, et al. Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study[J] Anticancer Res. 2007 May-Jun;27(3B):1527-1530.
[336]B?hnke A, Jung J, Taubert H, et al.Both somatic and germline genetics of the TP53-pathway influence ovarian cancer incidence and survival[J]. Verh Dtsch Ges Pathol. 2007;91:233-242.
[337]Gadducci A ,Cosio S,M uraca S,et al.Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer:Biological data and clinical implications [J].Eur J Gynaecol Oncol,2002,23(5):390-396.
[1]Watanabe Y, Ueda H, Etoh T, et al.A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer[J].Anticancer Res, 2007,27(3B): 1449-1452.
[2]Staub J, Chien J, Pan Y, et al.Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance[J]. Oncogene 2007,26 (34):4926–4978.
[3]栾英姿,李力,黎丹戎,等.五种卵巢癌耐药细胞系的建立及其部分耐药相关基因的表达[J].中华妇产科杂志,2004, 39(6):403-407.
[4]唐兆前,李力,张玮等.改良2 -△△CT法分析RNASET2基因在卵巢癌卡铂耐药细胞系中的差异表达[J]。肿瘤预防与治疗,2009,22(3):242-245.
[5]Soong R., Ruschoff,J. and Tabiti,K. Detection of colorectal micrometastasis by quantitative RT–PCR of cytokeratin 20 mRNA[J]. Roche Diagnostics internal publication,2000.
[6]张文晶,李红霞,宋磊,等.应用基因芯片技术筛选卵巢癌紫杉醇耐药差异表达基因[J].肿瘤防治研究,2006,33(1):32-35.
[7]VASE P A. Resistance to chemotherapy in advanced ovarian cancer :mechanisms and current strategies[J] . Br J Cancer , 2003 , 89 (Suppl3) : S23.
[8]曾益心肿瘤学[M].第二版第二次印刷,北京:人民卫生出版社,2003:97
[9]Fraser M, Bai T, Tsang BK.Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function[J]. Int J Cancer. 2008 ,122(3):534-546.
[10]Jin X, Burke W, Rothman K, et al.Resistance to p53-mediated growth suppression in human ovarian cancer cells retain endogenous wild-type p53[J]. Anticancer Res. 2002 ,22(2A):659-664.
[11]Wu H, Cao Y, Weng D, et al.Effect of tumor suppressor gene PTEN on theresistance to cisplatin in human ovarian cancer cell lines and related mechanisms[J]. Cancer Lett. 2008 ,28;271(2):260-271.
[12]袁才佳,聂新民.应用Real-time PCR对基因芯片结果的验证分析[J].现代医药卫生.2007,23(21):3187-3189.
[13]Tseng GC, Oh MK, Rohlin L,et al. Issues in cDNA microarray analysis: quality filtering, channel normalization,models of variations and assessment of gene effects[J] .Nucleic Acids Res, 2001, 29(12): 2549-2557.
[14]罗瑶,许宏,李瑶,等.表达谱基因芯片的可靠性验证分析[J].遗传学报,2003 , 30 (7) : 611-618.
[15]Yue H,Eastman P S,Wang B B,Minor J,et al.An evaluation of the performance of cDNA microarrays for detecti changes in global mRNA expression[J].Nucleic Acids Res,2001, 29(8): E41-1.
[16]Chaib H, Cockrell EK, Rubin MA, et al.Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis[J]. Neoplasia. 2001,3(1):43-52.
[17]Hembruff SL, Villeneuve DJ, Parissenti AM. The optimization of quantitative reverse transcription PCR for verification of cDNA microarray data[J]. Anal Biochem. 2005 ,345(2):237-249.
[18]Azim AC, Knoll JH, Marfatia SM, et al .DLG1: chromosome location of the closest human homologue of the Drosophila discs large tumor suppressor gene[J]. Genomics. 1995,30(3):613-616.
[19]Wang JC, Lv H, Gao X.et al.Expression and distribution of Dlg1 during meiotic maturation in mouse oocytes[J]. Biochem Biophys Res Commun. 2009. [Epub ahead of print]
[20]Vieira V, de la Houssaye G, Lacassagne E, et al.Differential regulation of Dlg1, Scrib, and Lgl1 expression in a transgenic mouse model of ocular cancer[J].2008,14:2390-2403.
[21]Fuja TJ, Lin F, Osann KE, et al.Somatic mutations and altered expression of the candidate tumor suppressors CSNK1 epsilon, DLG1, and EDD/hHYD in mammary ductal carcinoma[J]. Cancer Res. 2004,64(3):942-51.
[22]Guo W J, ZengM S, Yaday A, et al. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells [J]. Cancer Res,2007,67(11):5083-5089.
[23]Miyazaki K, Inoue H, Onai N, et al .Chemokine-mediated thymopoiesis is regulated by a mammalian Polycomb group gene, mel-18[J]. Immunol Lett. 2002,80(2):139-143.
[24]Li YJ, Chen ZC. Molecular cloning and characterization of LCRG1 a novel gene localized t o the tumor supp ress or locus D17S8002 D17S930 [ J ]. Cancer Lett, 2004, 209 (1) : 75-85.
[1] Balch C, Huang TH, Brown R, et al. The epigenetics of ovarian cancer drug resistance and resensitization[J]. AmJ Obstet Gynecol ,2004, 191(5):1552-1572.
[2] Staub J, Chien J, Pan Y, et al.Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance[J]. Oncogene,2007, 26(34):4969-4978.
[3] Watanabe Y, Ueda H, Etoh T, et al. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer[J].Anticancer Res, 2007, 27(3B): 1449-1452.
[4]Singal R,Ginder G D.DNA methylation[J],1999,93(12):4059-4070.
[5]Lund A H , Lohuizen MV.Epigenetics and Cancer[J].Genes Dev , 2004 ,18(19):2315-2335.
[6]Li M, Balch C, Montgomery JS, et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer[J].Li MBMC Med Genomics, 2009 , 8;2:34.
[7]Staub J, Chien J, Pan Y, et al. Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance[J] . Oncogene, 2007,26( 34) : 4969-4978.
[8]VASE P A. Resistance to chemotherapy in advanced ovarian cancer :mechanisms and current strategies[J] . Br J Cancer , 2003 , 89 (Suppl3) : S23.
[9]冯作化.医学分子生物学[M].第1版.北京:人民卫生出版社,2005:109.
[10]Chen H, Ye F, Zhang J,et al. Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma[J].Eur J Gynaecol Oncol,2007,28(6):464-467.
[11]Havrilesky L, Darcy M, Hamdan H, et al.Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study[J]. J Clin Oncol, 2003,21(20):3814-3825.
[12]M Mandail-V. I KonishiK T Komatsu. Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progressionand nm23 gene expression[J] .Britsh J burnal Cancer ,1995, 72:691-695.
[13]Chen H, Ye F, Zhang J, et al. Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma[J]. Eur J Gynaecol Oncol, 2007,28(6):464-467.
[14]Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell,2004;116:281-297.
[15]Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer[J]. Nat Rev Cancer,2006;6:259-269.
[16]Calin GA, Croce CM. MicroRNA signatures in human cancers[J]. Nat Rev Cancer,2006;6:857-866.
[17] Lee RC, Feinbaum RL, Ambros V . The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J].Cell, 1993 ,75(5):843-854.
[18]Liu J, Valencia-Sanchez MA, Hannon GJ, et al. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies[J].Nat Cell Biol, 2005 , 7(7):719-723.
[1]冯作化,医学分子生物学[M],第一次印刷第一版,北京:人民卫生出版社, 2005, 109
[2] Mandail-V M,KonishiK IT Komatsu,et al.Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression[J]. Britsh Journal of Cancer,1995, 72(3):. 691-695
[3]Schuldes H, Dolderer JH, Zimmer G, et al. Reversal of multidrug resistance and increase in plasma membrane fluidity in CHO cells with R-verapamil and bile salts[J]. Eur J Cancer ,2001,37(5):660-667.
[4]Samimi G, Fink D, Varki NM, et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy[J]. Clin Cancer Res. 2000 ,6(4):1415-1421.
[5]Damia G, Guidi G, D'Incalci M. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines[J]. Eur J Cancer, 1998 ,34(11):1783-1788.
[6]DabholkarM, Thornton K, Vionnet J, et al. Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues[J]. Biochem Pharmacol .2000 ,60(11):1611-1619.
[7]Mujoo K, Zhang L, Klostergaard J, et al. Emergence of cisplatin-resistant cells from the OVCAR-3 ovarian carcinoma cell line with p53 mutations, altered tumorigenicity, and increased apoptotic sensitivity to p53 gene replacement[J]. Int J Gynecol Cancer ,2000 ,10(2):105-114.
[8]Roy G, Horton JK, Roy R, et al. Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins[J]. Oncogene, 2000,19(1):141-150.
[9] Bazzett LB, Watkins CS, Gercel-Taylor C, et al. Modulation of proliferation and chemosensitivity by procathepsin D and its peptides in ovarian cancer. Gynecol Oncol 1999 Aug;74(2):181-187
[10]Appierto V, Cavadini E, Pergolizzi R, et al. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line[J]. Br J Cancer.2001, 84(11):,1528-1534.
[11] Kiyozuka Y, Yamamoto D, Yang J, et al. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells[J]. Anticancer Res ,2000 ,(1A):203-212.
[12]Ottone F, Miotti S, Bottini C, et al. Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines[J]. Br J Cancer 1997;76(1):77-82.
[13]Ogiso Y, Tomida A, Lei S, et al. Proteasome inhibition circumvents solid tumor resistanceto topoisomerase II-directed drugs[J]. Cancer Res , 2000 ,60(9):2429-2434
[14]Gadducci A ,Cosio S,M uraca S,et al.Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer:Biological data and clinical implications [J].Eur J Gynaecol Oncol,2002,23(5):390-396.
[15]Righetti SC, Perego P, Corna E, et al. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection[J]. Cell Growth Differ.1999 ,10(7):473-478.
[16]Perego P, Giarola M, Righetti SC, et al . Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems[J].Cancer Res. 1996,56(3):556-62.
[17]Campomenosi P,Salis S,Lindqvist C,etal.Characterization of RNASET2,the first human member of the Rh/T2/S family of glycoproteins[J]. Arch Biochem Biophys. 2006, 449(1-2):17-26.
[18]Acquati F, Possati L, Ferrante L, etal. Tumor and metastasis suppression by the human RNASET2 gene[J]. Int J Oncol. 2005,26(5):1159-1168.
[19]Monti L, Rodolfo M,Lo Russo G,etal. RNASET2 as a tumor antagonizing gene in a melanoma cancer model[J].Oncol Res. 2008, 17(2):69-74 .
[20]Lin F, Shi J, Liu H, et al. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus[J].Am J Clin Pathol. 2008 ,129(4):592-605.
[21]Osada R, Horiuchi A, Kikuchi N,et al. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma[J]. Hum Pathol. 2007 ,38(9):1310-1320.
[22]Wang Y, Pakunlu RI, Tsao W, et al .Bimodal effect of hypoxia in cancer: role of hypoxia inducible factor in apoptosis[J]. Mol Pharm. 2004,1(2):156-165.
[23]Lee S, Garner EI, Welch WR, et al. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma[J].Gynecol Oncol. 2007 ,106(2):311-317.
[24]Hasina R, Pontier AL, Fekete MJ, et al.NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype[J].Oncogene. 2006,25(4):588-598.
[25]Ripperger T, von Neuhoff N, Kamphues K,et al. Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle-cell lymphomas.Haematologica[J]. 2007,92(4):460-468.
[26]Myagmar BE, Umikawa M, Asato T, et al. PARG1, a protein-tyrosine phosphatase-associated RhoGAP, as a putative Rap2 effector[J]. Biochem Biophys Res Commun. 2005 ,329(3):1046-1052.
[27]Katoh Y, Katoh M. Identification and characterization of ARHGAP27 gene in silico[J]. Int J Mol Med. 2004 ,14(5):943-947.
[28]Garkavtsev I, Demetrick D, Riabowol K. Cellular localiza-tion and chromosome mapping of a novel candidate tumorsuppressor gene (ING1)[J]. Cytogenet Cell Genet, 1997,76(34): 176-178.
[29]Zeremski M, Horrigan SK, Grigorian IA, et al. Localizationof the candidate tumor suppressor gene ING1 to human chro-mosome 13q34[J]. Somat Cell Mol Genet, 1997, 23(3):233-236.
[30]Gunduz M, Ouchida M, Fukushima K, et al. Genomic structure of the human ING1 gene and tumor-specific mutation detected in head and neck squamous cell carcinomas[J]. Cancer Res, 2000,60(12):3143-3146.
[31]Toyama T, Iwase H, Wastson P, et al. Suppression of ING1 expression in sporadic breast cancer[J]. Oncogene,1999,18(37):5187-5193.
[32]Chen L, Matsubara N, Yoshino T, et al. Genetic alterations of candidate tumor suppressor ING1 in human esophageal squamous cell cancer[J]. Cancer Res, 2001,61(11):4345-4349.
[33]Oki E, Maehara Y, Tokunaga E, et al. Reduced expression of p33/ING1 and the relationship with p53 expression in human gastric cancer[J]. Cancer Lett,1999, 147(1-2):157-162.
[34]Shen DH, Chan KY, Khoo US, et al. Epigenetic and genetic alterations of p33ING1b in ovarian cancer[J]. Carcinogenesis,2005,26(4):855-863.
[35]梁燕华,何平平,杨森.多发性家族性毛发上皮瘤致病基因的确定[J].中华皮肤科杂志, 2005, 38(2): 71-73.
[36]Hildebrandt T, Preiherr J, TarbéN, et al. Identification of THW, a putative new tumor suppressor gene[J].Anticancer Res. 2000 ,20(5A):2801-2809.
[37]Singaravelu K, Devalaraja-Narashimha K, Lastovica B, et al. PERP, a p53 proapoptotic target, mediates apoptotic cell death in renal ischemia[J]. Am J Physiol Renal Physiol. 2009,296(4):847-858.
[38]Attardi LD, Reczek EE, Cosmas C, et al. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family[J].Genes Dev. 2000 ,14(6):704-718.
[39]Sarkar S, Pollack BP, Lin KT, et al. hTid-1, a human DnaJ protein, modulates the interferon signaling pathway[J].J Biol Chem. 2001 , 76(52):49034-49042.
[40] Paraoan L, Gray D, Hiscott P,et al.Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type[J]. Exp Eye Res. 2006 ,83(4):911-919.
[41]Edwards KM,Edwards KM, Münger K,et al.Depletion of physiological levels of the human TID1 protein renders cancer cell lines resistant to apoptosis mediated by multiple exogenous stimuli[J] .Oncogene. 2004 ,23(52):8419-8431.
[1]Ducasse M, Brown M A. Epigenetic aberrations and cancer[J].Mol Cancer,2006,5(1):60-75.
[2]Fegers I, Kob R, Eckey M, et al .The tumor suppressors p33ING1 and p33ING2 interact with alien in vivo and enhance alien-mediated gene silencing[J]. J Proteome Res.2007,6(11):4182-4188.
[3]Eckey M, Tenbaum SP, Mu?oz A, et al.Mixed lineage kinase 2 enhances trans-repression of Alien and nuclear receptors[J]. Mol Cell Endocrinol. 2003 ,213(1):71-78.
[4]Tenbaum SP, Papaioannou M, Reeb CA, et al.Alieninhibits E2F1 gene expression and cell proliferation[J]. Biochim Biophys Acta. 2007,1773(9):1447-1454.
[5]Vieyra D, Senger DL, Toyama T,et al.Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors[J]. Clin Cancer Res. 2003,9(16 Pt 1):5952-5961.
[6]Kameyama K, Huang CL, Liu D,et al .Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients[J]. Clin Cancer Res. 2003,9(13):4926-4934.
[7]Zhu Z, Lin J, Qu JH, et al .Inhibitory effect of tumor suppressor p33(ING1b) and its synergy with p53 gene in hepatocellular carcinoma[J]. World J Gastroenterol. 2005,11(13):1903-1909.
[8]Shen DH, Chan KY, Khoo US, et al .Epigenetic and genetic alterations of p33ING1b in ovarian cancer[J]. Carcinogenesis. 2005 ,26(4):855-863.
[9] Hildebrandt T, Preiherr J, TarbéN, et al. Identification of THW, a putative new tumor suppressor gene[J].Anticancer Res. 2000 ,20(5A):2801-2809.
[10]Hasina R, Pontier AL, Fekete MJ, et al.NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype[J]. Oncogene. 2006,25(4):588-598.
[11]Mankame TP, Zhou G, Lingen MW.Identification and characterization of the human NOL7 gene promoter[J]. Gene. 2010,456(1-2):36-44.
[12]Edwards KM, Munger K.Depletion of physiological levels of the human TID1 protein renders cancer cell lines resistant to apoptosis mediated by multiple exogenous stimuli[J]. Oncogene. 2004 ,23(52):8419-8431.
[13] Kim SW, Hayashi M, Lo JF, et al .Tid1 negatively regulates the migratory potential of cancer cells by inhibiting the production of interleukin-8[J]. Cancer Res. 2005 ,65(19):8784-8791.
[14]梁燕华,何平平,杨森.多发性家族性毛发上皮瘤致病基因的确定[J].中华皮肤科杂志,2005, 38(2): 71-73.
[15] Hutti JE, Shen RR, Abbott DW,et al.Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation[J].Cancer Res. 2004 ,64(15):5113-5117.
[16] Salhi A, Bornholdt D, Oeffner F, et al.Multiple familial trichoepithelioma caused by mutations in the cylindromatosis tumor suppressor gene[J].Mol Cell. 2009,34(4):461-72.
[17]李孟达,李玉洁,黄永文,等.影响上皮性卵巢癌远期疗效的因素分析[J].癌症杂志.2004,23(11):1306-1310.
[2]李巍,崔恒.卵巢癌诊断的研究进展,中华妇产科杂志,2005 40(7): 1994-2009.
[3]吴爱如.妇科恶性肿瘤的流行病学,中国肿瘤,1997,6(11):3-5.
[4]葛学顺. CA125、CA199联合检测对卵巢恶性肿瘤的诊断价值[J].检验医学与临床, 2007, 4(3): 177.
[5]蒋冬军,周伟珍.血清CA125联合TSGF、CA199检测在卵巢癌中的临床应用.当代医学,2008,10(7):79-80.
[6]Wu D H,Wu B Y,WangW H. Clinical value of serum CA19-9 and CA72-4 formalignant tumors ofdifferent organ of eldly[J]. China MultOrgan DisEldly, 2003, 2 (1): 561.
[7]庞晓冬.卵巢癌72例的B型超声诊断分析.中国肿瘤临床与康复,2001,8(1):62-63.
[8]汪小芬,何伟。彩超对卵巢癌的诊断价值[J].四川医学, 2009,30 (2):262-263
[9]梁英魁,郭勇.CT和血清肿瘤标记物在卵巢癌诊断和分期中的应用.中国医学影像学杂志,2006,14(2):87-91.
[10]吴湖炳,王全师,王明芳,等.PET/CT显像在探测卵巢癌术后复发、转移中的应用.中华核医学杂志,2006,26(4):197-200.
[11] Bar-shalom R,Valdivia A Y,Blaufox MD.PET imaging in oncology[ J ],Sem in NuclMed,2000,30(3):150-185.
[12]李亚冬,张桂杰。卵巢癌腹水101例脱落细胞学诊断价值[J].中国热带医学,2008,8(5):797-798.
[13]刘冬妍,董艳娥,等.比较血清CEA、CA199、CA125、CA724对卵巢癌临床诊断及疗效观察的价值.辽宁医学杂志,2002,16(1):17-18.
[14] Le T, Adolph A, Krepart GV,et al.The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.Gynecol Oncol, 2002,85(2):351-355
[15] Rubin SC. Surgery for ovarian cancer[J].Hematol Oncol Clin North Am. 1992 ,6(4):851-65.
[16] Takec I. Role of appendectomy in predicting lymph node metastases in patients with ovarian cancer. Eur J Obstet Reprod Biol, 2000,88(2):159-163
[17] Base T,Kosebay D,Kaleli S,etal.Appendectomy in the surgical staging of ovarian carcinoma. Int J Gynaecol Obstet,1996,53(3):249-252.
[18] Fawzi HW, Robertshaw JK, Bolger BS, et al.Role of appendicectomy in the surgical management of ovarian cancer.Eur J Gynaecol Oncol, 1997,18(1):34-35
[19] Kecmanovic DM, Pavlov MJ, Kovacevic PA, et al. Cytoreductive surgery for ovarian cancer. Eur J Surg Oncol,2003 ,29(4):315-320.
[20] Eltabbakh GH, Awtrey CS. Current treatment for ovarian cancer. Expert Opin Pharmacother, 2001 ,2(1):109-124.
[21] Di Re F, Baiocchi G. Value of lymph node assessment in ovarian cancer: Status of the art at the end of the second millennium. Int J Gynecol Cancer, 2000 ,10(6):435-442.
[22] Di Re F, Baiocchi G. Value of lymph node assessment in ovarian cancer: Status of the art at the end of the second millennium. Int J Gynecol Cancer, 2000 ,10(6):435-442.
[23] Yokoyama Y,Sakamoto T,Sato S,etal.Evaluation of cytoruductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer.Eur J Gynaecol Oncol,1999,20(5-6):132-366.
[24]Faught W, Le T, Fung Kee Fung M, et al. Early ovarian cancer: what is the staging impact of retroperitoneal node sampling? J Obstet Gynaecol Can,2003 , 25(1):18-21.
[25]Burghardt E,Pickel H,Lahousen M,et al.Pelvic lymphadenectomy in operative treatment of ovarian cancer.Am J Obstet Gynecol,1986,155(2):315-319.
[26]Kikkawa F,Ishikawa H,Tamakoshi K,et al.Prognostic evaluation of lymphadenectomy for epithelial ovarian cancer.J Surg Oncol,1995,60(4):227-231.
[27]Kigawa J,Minagawa Y,Itamochi H,et al.Retroperitoneal lymphadenectomy,including the para-aortic nodes in patients in patients with stageⅢovarian cancer.Am J Clin Oncol,1994,17(3):230-233.
[28]Saygili U, Guclu S, Uslu T,et al. Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stageⅢovarian carcinoma? A DEGOG Study. J Surg Oncol, 2002 ,81(3):132-137.
[29]Morice P, Camatte S, Wickart-Poque F,et al. Conservative management of malignant and borderline ovarian tumor.Bull Cancer,2002 , 89(12):1019-1026
[30]Morice P,Wicart-Poque F,Rey A,et al.Results of conservative treatment in epithelial ovarian carcinoma.Cancer,2001,92(9):2412-2418.
[31] Plante M.Fertility preservation in the management of gynecologic cancers .Curr Opin Oncol,2000,12:495-497.
[32]Zanetta G,Chiari S,Rota S,et al.Conservative surgery for stage I ovarian canrcinoma in women of childberaring age.Br J Obstet Gynaecal,1997,104(9):1030-1035.
[33]Morice P, Camatte S, Wicart-Poque F ,et al.Results of conservative management of epithelial malignant and borderline ovarian tumours.Hum Reprod Update.,2003,9(2):185-192.
[34]Ayhan A, Celik H, Taskiran C, et al.Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer.Eur J Gynaecol Oncol, 2003,24(3-4):223-232.
[35]Suzuki M , Tsukagoshi S, Ohwada M et al.A patient with brain metastasis from ovarian cancer who showed complete remission after multidisciplinary treatment. Gynecol Oncol ,1999,74(3):483-486.
[36] Piccart M J, Lamb H, Vermorken J B.Current and future potential roles of the platinum drugs in the treatment of ovarian cancer [J].Annals of Oncology, 2001,12(9):1195-1203.
[37] Onnis A ,Marchetti M, Padovan P et al. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynecol Oncol,1996,17:393-396
[38] Munkarrah AR, Hallum AV, Morris M et al.Prognostic significance of residual disease in patients with stageⅣepithelial ovarithelial ovarian cancer. Gynecol Oncol, 1997,64:13-17.
[39] Dauplat J, Bouedec G, Pomel C,et al.Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol ,2000,19(1):42-48.
[40] Tingulstad S, Skjeldestad FE, Hagen B.The effect of centralization of primary surgery on survival in ovarian cancer patients.Obstet Gynecol, 2003 ,102(3):499-505.
[41] Hamid D,Rohr S,Baldauf JJ,et al.Interest in intestinal resection for treatment of advanced ovarian cancer.Ann Chir,2002,127(1):40-47.
[42]Todo Y, Sakuragi N, Oikawa M, et al. Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma.Int J Clin Oncol, 2003 ,8(2):90-96.
[43]Balbi GC,Compagna R,Musone R, et al.Cytoreductive surgery in patients with stage IV ovarian carcinoma.Mineva Gynecol,2001, 53[Suppl 1]:105-109.
[44] Schorge JO, Wingo SN, Bhore R, et al.Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer[J]. Int J Gynaecol Obstet. 2010 Feb;108(2):123-127.
[45] Tian WJ, Jiang R, Cheng X, et al.Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction[J]. J Surg Oncol. 2010 Mar 1;101(3):244-250.
[46]Eisenkop SM, Friedman RL, Spirtos NM.The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.Cancer[J]. 2000, 88(1):144-153.
[47]Bae J, Lim MC, Choi JH, et al.Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer[J]. J Gynecol Oncol. 2009 ,20(2):101-106.
[48]McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].N Engl J Med, 1996, 334:1-6.
[49]Piccart MJ, Bertelsen K, Stuart G, et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophos- phamide-cisplatin combination in advanced ovarian cancer [J].Int J Gynecol Cancer,2003,13(suppl 2):144-148.
[50]Neijt JP,Engelbolm SA,Tuxen MK,et a1.Exploratory phaseⅢstudy of paclitaxd and clsplatin versus paclitaxd and carbo platin in advanced ovarian cancer [J].J Clin Oncol,2000,18(17):3084-3092.
[51]Dubois A,Lueek HJ,Meier W,et al.A randomized clinicaltrial of cisplati paclitaxel versus carboplatinJpaelitaxd as first-line treatment of ovarian cancer [J].J Natl Cancer Inst,2003,95(17):1320-1329
[52]Ozols RF, Brian N,Bundy, et al. Phase III trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study [J]. J Clin Oncol .2003;21:3194-3200
[53]Andreas dB, Hans JL, Werner M. A. Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer [J].J Natl Cancer Inst 2003,95(17):1320–1330.
[54]Muggia F,Braly P,Brady M,et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: Gynecologic Oncology Group study [J]. J Clin Oncol 2000, 18 (1):106-115.
[55]沈铿,李孟达,丰有吉等.泰素周疗和三周疗法作为卵巢癌一线化疗的多中心对照研究[J].中华医学杂志, 2005, 85(30):2099-2013.
[56] Hogberg T.Chemotherapy: Current drugs still have potential in advanced ovarian cancer[J]. Nat Rev Clin Oncol. 2010,7(4):191-193.
[57]Gadducci A,Carnino F,Chiara S,et a1.Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer:a randomized trial of the Gruppo OncologicoNord-Ovest [J].Gynecol Oncol,2000,76(2):157-162.
[58] polyzos A,Tsavaris N,Kosrnas C,at a1.A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stageⅢovarian cancer [J].Oncology,1999,56(1):191-196.
[59]Carrabin N, Mithieux F, Meeus P, et al Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer[J]. Bull Cancer. 2010 ,97(4):E23-32.
[60] Maurie Markman, P.Y. Liu, Sharon Wilczynski, et al.Phase III Randomized Trial of 12 Versus 3 Months ofMaintenance Paclitaxel in Patients With Advanced OvarianCancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial [J].J Clin Oncol, 2003, 21:2460-2465.
[61]Fleming GF,Toth BJ, Baker SD, et al.Phase I trial of aclitaxel and etoposide for recurrent ovarian cancer: a Gynecologic Oncology GroupStudy [J].Am J Clin,2000,23(6):609-613.
[62]Pignata S, Deplacido S, Scambia G, et al.Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer.multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study [J].J Clin Oncol, 2004, 22:2635-2642.
[63]成宁海,黄惠芳,潘凌亚等.晚期卵巢上皮癌的巩固化疗—一项前瞻性随机对照试验[J].解放军医学杂志,2006, 31(7):654-656.
[64] Amikura T, Aoki Y, Kase H, et al. Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy [J].Int J Clin Oncol, 2002, 7(1):45-50.
[65]McLean KA, Shah CA, Thompson SA, et al.Ovarian cancer in the elderly: Outcomes with neoadjuvant chemotherapy or primary cytoreduction[J]. Gynecol Oncol. 2010 Apr 26. [Epub ahead of print]
[66]Weinberg LE, Rodriguez G, Hurteau JA.The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer[J].J Surg Oncol. 2010,101(4):334-343.
[67]Tiersten AD, Moon J, Smith HO, et al.Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study[J]. Oncology. 2009;77(6):395-399.
[68]刘穗,刘继红,黄鹤等.上皮性卵巢癌复发的影响因素分析[J].癌症,2003,22(11):1197-1200.
[69] Pecorelli S, Odicino F, Favalli G.Ovarian cancer:best timing and applications of debulking surgery [J].Ann Oncol, 2000, 11(Suppl 3):141-144.
[70] Chi DS,Liao JB,Leon LF,et al.Identification of prognostic facter in advanced epithelial ovarian carcinoma [J].Gynecol Oneol,2001,82(3):532-537.
[71] Bristow RE,Tomacruz RS,Arm strong DK,et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:ameta-analysis [J].J Clin Oncol,2002,2O:1248-1259
[72]Gore M, Mainwaring PA, Hern R, et al.Randomized trial of dose-intensity with single-agent carboplatin patients with epithelial ovarian cancer [J].J Clin Oncol, 1998, 16(7):2426-2434
[73] Jakobsen A, Bertelsen K, Andersen JE, et al.Dose-Effect Study of Carboplatin in Ovarian Cancer:A Danish Ovarian Cancer Group Study [J].J Clin Oncol, 1997, 15 (1): l93-198.
[74] Kaye SB, Pau1 J, Cassidy J, et al. Mature results of a randomize(1 trial of two doses of cisplatin for the treatment of ovarian cancer.St·0ttish Gynecology Cancer Trials Group [J].J Clin Oncol, 1996, 14(7):21l3-21l9
[75]Conte PF,Bruzzone M,Camino F,et al.High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer:A randomized study of the gono [J].J Clin Oncol,1996,l4(21):351-356
[76] Dittfich CH,Sevelda P,alzer H,et al.Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients.10 year results of a prospective randomised phase III study comparing carboplatin-cisplatin with Cyclophosphamide-cisplatin[J].Eur J Cancer2003,39(81):ll29-1140
[77]Joly F,Heron JF,Kerbrat P,et al.High-dose platinum versus startdard dose in advanced ovarian carcinoma:a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers(FNCLCC) [J].Gynecol Oncol,2000,78(3 pt1):361-368.
[78] Hakes TB, Chalas E, Hoskins WJ, et a1.Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma [J].Gynecol Oncol 1992;45:284–289.
[79]Bertelsen K, Jakobsen A, Stroyer J, et a1. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide,adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Cancer Group Study [J].Gynecol Oncol,1993,49:30–36.
[80] Lambert HE, Rustin GJSD, Gregory WM, et a1.A randomized trial of five vesus eight courses of cisplain or carboplatin in advanced epithelial ovarian cancer [J].Ann Oncol 1997,8:327–333.
[81] Rosenberg PA,Andersson HA,Boman KA,et al.Randomized trial of single-agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum [J].Acta Oncol 2002, 41(5):418-424.
[82] Watanabe Y,Nakai H,Ueda H,et a1.Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer [J].Gynecol Oncol,2005,96(2):323-329
[83]Bolis GA,F avalli GA, Danese SA et al.weekly cisplatin given for 2 moths versus cisplatin plus cyclophamidegiven for 5moths after cytoreductive surgery for advance dovarian cancer [J].J Clin Oncol, 1997,15(5):1938-1944.
[84]Cocconi GA, Bella MA, Lottici RA, et al. Mature results of prospective randomized trial comparing a three-weekly with an acceleeated weekly schedule of cisplatin in advance ovarian carcinoma [J].Am J Clin Oncol, 1999, 22(6):559-567
[85]李彩云,张才兴,高雪梅等.卵巢癌术后腹腔温热灌注联合化疗疗效观察[J].人民军医,2007,50(2):87-89
[86]夏宗懿,戴志远.晚期卵巢癌预后影响因素分析[J].苏州医学.2003,26(2):73-74
[87]连利娟等.林巧稚妇科肿瘤学.北京,人民卫生出版社,2001,p585.
[88]唐勇,李力,唐兆前等.卵巢上皮癌术后化疗期间血清CA125检测与其预后关系的研究[J].中国癌症防治杂志.2009,1(1):36-38.
[89]Nakayama K, Takebayashi Y, Nakayama S, et al.Prognostic value of over expression of P53 in human ovarian carcinoma patients receiving ciplatin [J].Cancer Lett, 2003, 192:227-235.
[90]王绍娟,魏萍,李家梅等.卵巢癌基因表达与化疗疗效及预后相关性的研究[J].临床和实验医学杂志,2006,5,(10):1548-1549.
[91]傅士龙,张国玲,李子庭等.卵巢癌p53、MDR1、GST-π基因的共表达与化疗疗效的相关性[J].世界肿瘤杂志.2002,l(2):99-102.
[92]魏风华,赵晓东,张毅.铂类联合紫杉醇对晚期卵巢癌一线化疗疗效预测因素的研究[J].中华医学杂志.2007(87)l7:1187-1189.
[93] Sui L, Dong Y, Ohno M , et al. Inverse expression of cdk4 and p16 in epithelial ovarian tumours [J].Gynecol Oncol, 2000, 79(2):230-237.
[94]Masciullo V, Ferrandina G, Pucci B,et al. P27kipl expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariated analysis [J].Clin Cancer Res, 2000, 6(12):4816-4822.
[95] Sui L, Tokucla M, Ohno M, et al.The concurrent expression of P27kipl and cyclinD1 in epithelial ovarian tuours [J].Gynecol Oncol, 1999, 73(2):202-209.
[96]邹劲林,刘富元.卵巢上皮癌P27和Bcl-2表达及其意义[J].肿瘤学杂志, 2004, 10(5)302-304.
[97]Schuyer M, Van der Burg MEL, Henzen-Logmans SC, et al.Reduced expression of BAX is associated with epithelial ovarian cancer: a multifactorial analysis of TP53、P21、BAX AND Bcl-2 [J].Br Cancer, 2001, 85(9I:1359-1367.
[98]Lohmann CM, League AA, Clark WS, et al. Bcl-2:bax and bcl-2: bcl-x ratios by image cytometric quantitation of immunothemical expression in ovarian carcinoma correlation with prognosis [J].Gytometry.2000, 42(1):61-66.
[99]刘颖晖,刘宝宜,宋和存等.卵巢上皮癌中nm23基因蛋白的表达及其意义[J].中国医科大学学报, 2001,30(2):114-116.
[100] Paley PJ, Staskus KA, Gebhard K, et al.Vascular endothelial growth factor expression in early stage ovarian carcinoma [J].Cancer, 1997, 80(1):98-106.
[101] Yokoyama Y,Charnock-Jones DS, Licence D, et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma [J].Br J Cancer,2003, 88:237-244.
[102]李力,王丽梅,张玮等.卵巢恶性肿瘤患者测定血清血管内皮生长因子的临床价值[J].中华妇产科杂志, 2003, 38(2):72-76.
[103]徐军,张国玲,赵明等.血清VEGF表达与卵巢癌患者化疗疗效相关性的初步研究肿瘤[J].2000,20(2):114-115.
[104]Ferrandina G,lauriola L,zannoni G F,et al.Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and outcome in ovarian cancer patients [J].Ann Oncol,2002, 13(8):l205-l2l1.
[105] Raspollini MR,amunni G,villanucci A,et al.Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170(MDR1) expression is associated with chemotherapy resistance andpoor prognosis:analysis in ovarian carcinoma patients with low and high survival [J].Int J Gyn Cancer,2005,15(2):255-260.
[106]潘珊,吴绪峰,陈惠祯.上皮性卵巢癌组织中环氧化醇2的表达与化疗耐药及预后的相关性研究[J].肿瘤,2007, 27(1):46-50.
[107] Ostanin AA, Chernykh HR, Leplina OY, IL-2-Activated Killer Cells and Native Cytokines in Treatment of Patients with Advanced Cancer.Russ J Immunol, 1997 ,2(3-4):167-176.
[108] Lum LG,Lefever AV,Treisman JS,et al.Immune Modulation in Cancer Patients After Adoptive Transfer of Anti-CD3/Anti-CD28-Costimulated T Cells-Phase I Clinical Trial.J Immunother, 2001 ,24(5):408-419.
[109]Marme A, Strauss G, Bastert G,et al. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma.Int J Cancer, 2002 ,101(2):183-189.
[110] Melichar B, Savary CA, Patenia R, et al. Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma.Int J Gynecol Cancer, 2003 ,13(4):435-443.
[111]Berek JS,Stonebraker B,Lentz SS,et al.Intraperitoneal alpha-interferon in residual ovarian carcinoma:a phase II gynecologic oncology group study .Gynecol Oncol,1999,75:10-14.
[112] Santin AD,Ioli GR,Hiserodt JC,et al.Development and characterization of an IL-4-secreting human ovarian carcinoma cell line. Gynecol Oncol,1995,58(2):230-239.
[113] D'Incan C, Sanches R, Kuiper M, et al. Gamma-interferon gene transfer as a therapeutic strategy for ovarian cancer[J].Adv Exp Med Biol,1998,451:349-52.
[114]Bernhard H, Salazar L, Schiffman K,et al. Vaccination against the HER-2/neu oncogenic protein.Endocr Relat Cancer, 2002,9(1):33-44.
[115]Linehan DC, Peoples GE, Hess DT, et al.In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour. Surg Oncol, 1995,4:41-49.
[116]Brossart P. Dendritic cells in vaccination therapies of malignant diseases.Transfus Apheresis Sci, 2002 ,27(2):183-186.
[117]Reinartz S,Boerner H,Koehler S,et al.Evaluation of immunological responses in patients with ovarian cancer the anti-idiotype vaccine ACA125 by determination of intracellular cytokines-a preliminary report .Hybridom,1999,18:41-45.
[118]Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ,et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.Oncogene, 2003 ,22(3):370-380.
[119]Grove JI, Lovering AL, Guise C,et al. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.Cancer Res, 2003,63(17):5532-5537.
[120]Alvarez RD, Barnes MN, Gomez-Navarro J,et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.Clin Cancer Res, 2000,6(8):3081-3087.
[121]Wen SF, Mahavni V, Quijano E,et al. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer.Cancer Gene Ther, 2003 ,10(3):224-238.
[122]Buller RE, Runnebaum IB, Karlan BY, et al.A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.Cancer Gene Ther,2002,9(7):553-566.
[123]Saga Y, Mizukami H, Takei Y,et al. Suppression of cell migration in ovarian cancer cells mediated by PTEN overexpression.Int J Oncol, 2003 ,23(4):1109-1113.
[124]Qian GZ, Cao SJ,et al. The experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN-gamma genes.Int J Gynecol Cancer, 2002 ,12(1):80-85.
[125]Qian AJ, Kuhlcke K,et al. Multidrug resistance 1 gene transfer can confer chemoprotection to human peripheral blood progenitor cells engrafted in immunodeficient mice.Hum Gene Ther, 2002 ,13(2):233-242.
[126]Takahashi S, Hatake K, Sugimoto Y. Gene therapy for breast cancer.Gan To Kagaku Ryoho, 2003 ,30(4):468-477.
[127] Kohno T, Mizukami H, Suzuki M,et al. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer.Cancer Res, 2003 ,63(16):5091-5094.
[128] Mu J, Abe Y, Tsutsui T,et al. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.Jpn J Cancer Res, 1996 ,87(9):963-971.
[129]Han xiaohong,Gai xiaodong,Xue yanjian.On cancer multidrugresistance reversal [J].Journal of Bei Hua University ( NationalScience),2005,6(1):36-37.
[130]Zhou Jun,Liu Min,Luthra R,et al.EM012,a microtubule-interfering agent,inhibits the progression of multidrug resistant human ovarian cancer both in cultured cells and in athymic nude mice [J].Cancer Chemother Pharmacol,2005,55(5):461-465.
[131]卢丹,王志学.卵巢癌组织中多药耐药基因蛋白表达及其临床价值[J].肿瘤防治杂志,2004,11(5):512-514.
[132]熊丽丽,田晓予.PKCα、PKCε及P-gp在卵巢癌中的表达及其临床意义[J].广东医学2006;27(7):1026-1028.
[133] Hille S,Rein DT,Riffelmann M,et al.Anti-cancer drugs induce mdr1 gene expression in recurrent ovarian cancer [J]. Anticancer Drugs.2006,17(9):1041-1044.
[134] Cole SP,Deeley RG.Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP [J].Bioessays,1998,20(11):931-940.
[135] Laochariyakul P,Ponglikimongkol M,Mankhetkom S,Functional study of in tracellular P-gp and MRP-1 mediated pumping of free cytosolic pirarubic in into acidic organe cells in intrinsic resistant Siha cells [J].Can J Physiol Phamaco.2003,81(8):790-799.
[136]张树荣.卵巢癌组织中MDR1、survivin、topoII的表达及临床意义[J].中国妇幼健康研究,2006,17(6):564-465.
[137] Yakirevich E,Sabo E,Naroditsky I,et al. Multidrug resistance related phenotype and apoptosis-related protein expression in ovarian serous carcinomas [J].Gynecol Oncol,2006,100 (1):152-159.
[138] Wang W,Ke S,Chen G.Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines [J].Oncol Rep,2004,12(6):1365-1367
[139] Larsen AK,Escargueil AE,Skladanowski A.Resisance mechanisms associated with altered intracellular distribution of anticancer agent [J].Pharmacol Ther, 2000,85(3):217-229.
[140] Jia P,Wu S,Li F, et al.Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells [J].Int J Gynecol Cancer. 2005,15(6):1042-1048.
[141]Nagle CM,Chenevix-Trench G,Spurdle AB,et al.The role of glutathione-S-transferase polymorphisms in ovarian cancer survival [J].Eur J Cancer. 2007,43(2):283-290
[142]Morari EC,Lima AB,Bufalo NE. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients [J]. J Cancer Res Clin Oncol, 2006, 132 (8):521-528.
[143]Selvakumaraa M ,Pisarcik DA,Bao R.Enhanced cisplatin cytotoxicity by disturbing thenucleotide excision repair pathway in ovarian cancer cell lines [J].Cancer Ras, 2003, 63(6),1311-1316.
[144] Helleman J,van Staveren IL,Dinjens WN,et al.Mismatch repair and treatment resistance in ovarian cancer [J].BMC Cancer,2006,6:201-210.
[145] Duan Z, Duan Y, Lamendola DE, et al. Overexp ression of MAGE /GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines [J].Clin Cancer Res, 2003, 9 (7): 2778-2785.
[146] Kennedy RD, Quinn JE, Mullan PB, et al.The role of BRCA1 in the cellular response to chemotherapy [J].J Natl Cancer Inst.2004,96(22):1659-1668.。
[147]Yang X, Zheng F,Xing H,et al.Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and 0verexpression of anti-apoptotic proteins in ovarian cancer [J].J Cancer Ras Clin Oncol,2004,130(7):423-428
[148] Abedini M R,Qiu Q ,Yan X,et al.Possible role of FLICE-like inhibitory protein(FLIP)in chemoresistant ovarian cancer ceils in vitro [J].Oncogene,2004,23(42):6997-7004
[149]Yang X,Xing H,Gao Q,et al.Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells [J].Gynecol Oncol, 2005, 97(2):413-421
[150] Gadducci A ,Cosio S,M uraca S,et al.Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer:Biological data and clinical implications [J].Eur J Gynaecol Oncol,2002,23(5):390-396.
[151] 116.Skirnisdottir I, Seidal T , Gerdin E,et al.The prognostic importance of p53,bcl-2,and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy [J].Int J Gyneeol Cancer,2002,12(3):265-276.
[152] Lee S,Choi EJ,Jin C,et al.Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line [J].Gynecol Oneol,2005,97(1):26-34.
[153]夏婷.卵巢癌中PKC和P-gp的表达极其临床意义[J].肿瘤防治研,2005,32(3):152-154.
[154]Ateller MD,Shaw TJ,Vanderhyden BC,et al.Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells [J].Mol Cancer Res,2005,3(1):50-61.
[155] ParkSJ,Armstrong S,Kim CH,et al.Lack of ecg receptor contributes tu drug sensitibity of human germline cells [J].Br J Cancer,2005,92(2):334-341.
[156]Abuharberk S,Apel J,Zugmaier G,et al.Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV3 ovarian carcinoma cells [J]. Naunyn Schmiedebergs Arch Pharmacol,2005,371(2):141-151.
[157]RangelLB,Agarwal1R,D.SouzaT,etal. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas [J]. Int J Clin Cancer Res, 2003,9:2567-2575.
[158] Santin AD,CanS,BelloneS,et al. Treatment of chemotherapy-resistant human ovarian cancer xenografts in CB-17/SCID mice by intraperitoneal administration of clostridium perfringens enterotoxin [J].Cancer Res,2005,65(10):43340-4342.
[159] Katano K,Safaei R,Samimi G,et al.The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells[J].Mol Pharmacol,2003,6(2)4:466-473.
[160] Nakayama K,Kanzaki A,Ogowa K,et al.Copper-transporting p-type adenosine triphosphatase(ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma:comparative analysis with expression of MDR1,MRP1,MRP2,LRP and BCRP[J].Int J Cancer,2002,101(5):488-495.
[161]Sudo T, Nitta M, Saya H,et al.Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint [J].Cancer Res,2004,64(7):2502-2508。
[162]梁川,吴绪峰,陈慧君.卵巢癌中MDR1的表达及其临床意义[J].肿瘤防治研究.2008.35(10): 723-726.
[163]张素娟,闫洪超,薛加强.MDR1基因在上皮性卵巢癌组织中的表达及临床意义[J].实用诊断与治疗杂志.2007,21(7):515-516.
[164] Kolfschoten GM,Hulscher TM,Pinedo HM,et al.Drug resistancefeatures and S-phase fraction as possible determinants for drug responsein a panel of human ovarian cancer xenografts [J] .Br J Cancer,2000,83(7):921-927.
[165]Brinkhuis M,Izquierdo MA,Baak JP,et al.Expression of multidrug resis tance-associated markers,their relation to quantitative pathologic tumour cha- racterristics and prognosis in advanced ovarian cancer [J]. Anal Cell Pathol.2002,24(1):17-23.
[166] Beeghly A,Katsaros D,Chen H,et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival [J].Gynecol Oncol. 2006,100(2):330-337.
[167] Watanabe Y, Ueda H, Etoh T, etal A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer[J].Anticancer Res, 2007, 27(3B): 1449-1452.
[168]Strathdee G, MacKean MJ, Illand M, et al .A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer[J]. Oncogene. 1999 ,18(14):2335-2341.
[169]Obata H,Yahata T,Quan J,et al Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer [J].Anticancer Res,2006,26 (3B):2227-2232.
[170]WilliiamsJ,Lucas PC,Griffith KA,et al.Expression of BCL-XL in ovarian carcinoma is associated with chemoresistance and recurrent disease [J]. GynecolOncol, 2005, 96 (2):287-295.
[171]Spentzos D, Levine DA, Kolia S,et al.Unique gene expression profile based on pathologic response in epithelial ovarian cancer[J]. J Clin Oncol. 2005,23(31):7911-7918.
[172]Spentzos D, Cannistra SA, Grall F, et al.IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer[J]. Endocr Relat Cancer. 2007 ,14(3):781-790.
[173]Hartmann LC, Lu KH, Linette GP, et al.Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy[J]. Clin Cancer Res. 2005,11(6):2149-2155.
[174]Protopapas A, Diakomanolis E, Bamias A, et al.Michalas SThe prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D inovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy[J]. Eur J Gynaecol Oncol. 2004;25(2):225-229.
[175]Cannistra S.Is there a best choice of second-line agent in the treatment of recurrent ,potentially platinum-sensitive ovarian cancer [J] ClinOncol, 2002, 20(5): 1158-1160.
[175]孙红,张惜阴,丰有吉.重组白细胞介素2联合化疗治疗卵巢癌复发和转移灶的探讨[J] .中国肿瘤生物治疗杂志.1 9 9 9,6 ( 4 ) :312-313.
[176]林宏伟,栗敏,刘晶。奥沙利铂联合吉西他滨治疗难治性卵巢癌临床观察[J].山东医药2 0 0 9年第4 9(3 2):86-87.
[177] Breidenbach M, Rein DT, Mallmann Peter, et al.Individualized long-term chemotherapyfor recurrent ovarian cancer after failing high-dose treatment [J].Anti-CancerDrugs, 2 0 02;13(2):173-176.
[178] Dizon DS,Dupont J,Anderson S,et al.Treatment of recurrent ovarian cancer:a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel:The Memorial SloanKettering Cancer Center experience [J].Gynecol Oncol,2003,91(3):584-590.
[179]Eisenhauer EA,Ten Bokkel Huhmlk W ,wcncrton KD,et a1.European-Canadian ran domized uial of paclitaxel in re1apsed ovarian cancer: high-dose versus low-dose and long versus short infusion [J].J Clin Onco1.1994.12 f12):2654-2666.
[180] Sugiyama T, Yakushiji M, Nishida T, et a1. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer[J]. Cancer Lett. 1998 Jun 19;128(2):211-218.
[181] FenneHy D, Aghajanjan C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administrated weekly in patients with relapsed ovarian cancer [J].J Clin Oncol,1997,15(1):187-192
[182]Rose PG,Fusco N,Fluelen L,et al.Second-line therapy with paclitaxel and carboplatin for recurent disease following first-line therapy with paclitaxel and platinum in ovarianor peritoneal carcinoma [J].Clin Oncol,1998,16(4):1494-1497
[183]ParmarMK,Ledermann JA,Colombo N,et al.Paclitaxel plus platinum-based chemotherapy versus conventionalPlatinum-based chemotherapy in women withrelapsed ovarian cancer:the ICON4/AGO-OVAR-2.2 trial [J].Lancet,2003,361(9375):2094-2095.
[184] Du Bios A,Luck HJ,Pifsterer J,et al.Sencond-line carboplatin and gemcitabine in platinum sensitive ovarian cancer-a dose finding study by the AGO ovarian cancer study group [J].Ann Oncol,2001,12(8):1115-1112.
[185] Kose MF, Sufliarsky J, Beslija S, et al. A pIlase II study of gemeitabine plus carboplatin in platinum-sensitive,recurrent ovarian carcinoma [J].Gynecol Oneal ,2005,96(2):323-329.
[186]Covens A,Blessing J,Bender D,et al.A phase 1I evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer:A Gynecologic Oncology Group study [J].Gynecol Oneul,2006,100(3):586-590.
[187] M eyer T, Nelstrop AE,Mahmoudi M ,et al.Weekly cisplatin an doral etoposide as treatm ent for relapsed epithelial ovarian cancer [J].Ann Oncol,2001,12(12):1705-1709
[188] Morgan RJ Jr,Braly P,Leong L,et al.Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer:long-term follow-up [J].Gynecol Oncol,2000,77(3):433-438.
[189] Sundar S,Symonds RP,Decatris MP,et al.Phase II trial of Oxali platin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum based therapy [J].Gynecol Oncol,2004,94:502-508.
[190]McGuire wP,Blessing JA,Bookman MA,et al.Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma :a GOG study [J].J Clin Oncol,2000,18(5):1062-1067.
[191]Gordon AN,Fleagle5r,Guthrie D,et al.Recurent epithelial ovarian carcinoma randomized phase Ill study of pegylated liposomal doxorubicin versus topotecan [J].J Clin Onco l,2001,19(141):3312-3322.
[192] Markman M ,Iseminger KA,Hatch KD,et al.Tamoxifen in platinum -refractory ovarian cancer:a GOG an cillary report [J].Gyneco1 Oncol,1996,62:4-6
[193] Benedetti Panici P,Greggi S,Amoroso M,et al.A combination of platinum and tamoxifen in advan ced ovarian cancer failing platinum-based chemotherapy: results of a PhaseⅡstudy [J].Int J Gynecol Cancer, 2001,11(6):438-444
[194] Haniani P,Nolte S,Shahin MS,et al.Phase lI evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer [J].Gynecol Onco l,2002,85(2):278-284.
[195] Gore M,Huinink WB,Carmichael J,et al.Clinical evidence for topotecan -paclitaxel non-cross-resistance in ovarian cancer [J].Clin Oncol,2001,19(7):1893-1900.
[196]Markmean M .Intraperitoneal therapy of ovarian cancer [J].Semin Oncol, 1998, 25 (3):356-360.
[197] Legros M,Dqulplat J,Heury J,et a1 High-dose chemonthrapy with hematopoietic rescue in patients with stage III to IV ovarian cancer:long-term results [J].J Clin Oncol,1997, 15(4):1302-1308.
[198] Nahhas W A.Ovarian cancer:Curent outlook on the deadly disease[J].Postgrad Med, 1997,102(3):112-120.
[199] Markman M ,Kennedy A,Sutton G,et al.Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent [J].Gynecol Oncol,1998,70(2):272-274.
[200] Nahhas W A.Ovarian cancer:Curent outlook on the deadly disease[J].Postgrad Med, 1997,102(3):112-120.
[201]Piccart MJ,GreenJA,Lacave AJ,et al.Oxaliplatin or paclitaxel in patients with plaunum -pretreated advan ced ovarian cancer:a randomized phase lI study of the European organization for research and treatment of Cancer Gynecology Group [J].J Clin Oncol,2000,18(6):1193-1202.
[202]Gareia AA,O’Meara A,Bahador A,et al.Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer [J].Gynecol Oncol,2004,93 (2):493 -498.
[203]Bookm an MA,M almstrom H,Bolis G,et al.Topotecan for the treatment of advanced epithelial ovarian cancer:an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel [J].J Clin Oncol,1998,16(10):3345-3335.
[204] Gershenson DM,Burke TW,Morris M,et al. A phase I study of a daily X3 schedule of intrax enous vinorelbine of refractory epithelial ovarian cancer [J].GynecolOncol,1998,70(3):404-409.
[205]Marklilan M.Second-1ine treatment of ovarian cancer with single-agent gemcitabine [J].Semin Onco1,2002,29(1):9-10.
[206]Aravantinos G,Bafaloukos D,Fountzilas G,et al.Phase II study of docetaxel-vinorolhine in platinum-resistant,paelitaxel-pretreated ovarian cancer [J].Ann Oncol, 2003, 14(7) :1094-1099.
[207]Cohn DE,Valmadre S,Resnick KE,et al.Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer [J].Gynecol Oncol,2006,1 02(2):134- 139.
[208]Raspagliesi F, Zanaboni F, Vecchione F,et al.Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane[J]. Oncology, 2004,67(5-6):376-81.
[209]du BA,Meier W,Luck HJ,et al.Chemotherapy versus hormonal treatment in platinum-and paclitaxel-refractory ovarian cancer:a randomized trial of the German AGO study group ovarian cancer [J].Aim Oncol,2002,13(2):251-257.
[210] Penson RT,SupkoJG,Seiden MV,et al.A phase I- II study of 96-hour infusional topotecaB and paclitaxel for padents with recurrent mullerian tumors [J]. Cancer, 2001,92(5):l156-l167.
[211]Fleming GF,Waggoner SE,Rotmensch J.et al.Absence of major peripheral neuropathy in a phaseⅡtrial ofifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel [J].AmJ Clin Onco1,2001,24(1):52-57.
[212]Gordon AN, Fleagle JT, Guthrie D, et al.Recurent epithelial ovarian carcinoma randomized phase III study of pegylated liposomal doxorubicin versus topotecan [J].J Clin Onco l,2001,19(141):3312-3322.
[213]Petru E, Angleitner-Boubenizek L, Reinthaller A, et al. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study[J]. Gynecol Oncol. 2006 Aug;102(2):226-229.
[214]Thigpen T .The role of gemcitabine-based doublets in the management of ovarian carcinoma [J].Semin Oncol,2002,29(1):l1-l6.
[215] Rose PG, Rodriguez M, Walker J,et al.A phase 1 trial of prolonged oral etoposide and liposomal doxorubicin in ovarian peritonea1 and tubal carcillonla:a GOG study[J]. Gynecol Onco1,2002,85:136-l39.
[216]Rocereto TI,Sanl HM.AikiI1s IA.et al.PhaseⅡstudy of mifepristone(RU486)in refractory ovarian cancer [J].Gynecol On.co1,2000,77(3):429-432.
[217]Gore ME, Atkinson RJ, Thomas H, et al. Results of ZD0473 in platinum- pretreated ovarian cancer:analysis according to platinum free interval [J].Eur J Cancer, 2002, 38(Suppl 8):S7-12.
[218] Blackledge G.Cancer drugs:the next 10 years [J].Eur J Cancer, 2003, 39(3):273.
[219] Gronlund B, Hogdall C, Hansen HH, et al.Performance status rather than age is the key prognostic factor in second2line treatment of elderly patients with epithelial ovarian carcinoma [J].Cancer, 2002, 94(7):1961-1967.
[220]Molitemi A,Menard S,Valagussa P,et al.HER2 overexpression and doxorubiein in adjuvant chemotherapy for respectable breast cancer [J].J Clin Oncol,2003,21:458-462.
[221]赵晓东,张毅,何淑蓉等.P53表达对晚期上皮性卵巢癌一线化疗方案选择的意义[J].癌症.2005,24(12):1542-1554.
[222]赵晓东,张毅等,复发卵巢上皮癌“常规化疗药物疗效预测分子靶向化疗”的初步探讨[J].现代妇产科进展,2006;15(4):265-267.
[223]Zhao XD, Wei FH, Zhang Y, et al.Treatment of platinum-resistant recurrent ovarian cancer using a "predictive molecule targeted routine chemotherapy" system[J]. Chin Med J (Engl). 2009 ,122(23):2856-2860.
[224] Omura GA,Brady MF,Look KY,et al.Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study [J].J Clin Oncol. 2003,21(15):2843-2848.
[225]Vasey PA,Atkinson R,Coleman R,et al.Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer [J].Br J Cancer. 2001 Jan;84(2):170-178.
[226] Ledermann JA,Herd R,Maraninchi D,et al.High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT) [J].Ann Oncol.2001,12(5):693-699.
[227]Nieboer P,de Vries EG,Mulder NH,et al.Long-term haematological recovery following high-dose chemotherapy with autologous bone marrow transplantation or peripheral stem cell transplantation in patients with solid tumours [J].Bone Marrow Transplant. Bone.2001,27(9):959-966.
[228]林元藻.反义核酸的研究及应用[J].广东药学院学报,2000,16(1):48
[229]Tong Y,Pan L,Zhou S.Study of mdr1 antisense oligodeoxynucleotides on renersal of multidrug resistance in ovarian carcinoma cell line SKOV3 [J] .Zhonghua Fu chan Ke Za Zhi,2003,35(11):677-679.
[230]TouboulM,Gauchez AS,D Hardemare A du M,et al. Early detection of chemoresistance in vivo through the use of a radiolabeled antisense oligonucleotide [J].Anticancer Res,2002,22(6A):3349-3356.
[231]Masanek U,Stammler G,Volm M.Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of p-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides [J].ExpThher Oncol,2002,2(1):37-41.
[232]Zhang T,Guan M,et al. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells [J].Gynecol Oncol. 2005,97(2):501-507.
[233] Wu H,Hait WN,Yang JM,et al.Small Interfering RNA induced Suppres- sion of MDR1(P-Glycoprotein) Restores Sensitivity to Multidrug resistant Cancer Cells [J].Cancer Res,2003,63(4):1515-1519.
[234]张晓菁,温泽清,张华玲,等.小干扰RNA抑制多药耐药基因表达并逆转耐药[J].中国实用妇科与产科杂志.2006,22(1):29-31.
[235]Kobayashi H,Takermura Y,Wang FS,et al.Retrovirus-mediated transfer of anti-MDR-1 hammerhead ribozymes into multidrug-resistant human leukemia cells:screening of effective target sites [J].Cancer,1999,81;944-950.
[236]Nagata J,Kijima H,Hatanaka H,et al.Reversal of drug resistance usinghammerhead ribozymes against multidrug resistanceassociated protein and multidurg resistance 1 gene[J].Oncol,2002,2195:1021-1026.
[237]杨晓葵,邢辉,高庆蕾,等.mdr-1特异性核酶逆转卵巢癌的多药耐药[J].中华肿瘤杂志,2003,25(5):425-427.
[238]Wen SF,Mahavni V,Quijano E,et al.Assessment of p53 gene transfer and biological activities in a clinical study of ademovires-p53 gene thetapy for recurrent ovarian cancer [J].Cancer Gene Thet.2003,10(3):224-238.
[239]Vasey PA,Shulman LN,CamposS,et al.Phas I trial ofin traperitoneal in jiection of the E1B-55-kd gene deleted adeno virus ONYX-015,given on days 1 through 5 every 3 weeks in patients with recurren/refratory epithelial ovarian cancer[J].Cline Oncol.2002.20(6):1562-1569.
[240]Bentires A IjM,Barbu V,Fillet M,et al.NF-kappa B transcription factor induces drug resistance through MDR1 expression in cancer cells [J].Oncogene ,2003,22(1):90-97.
[241]戴春岭,符立梧.肿瘤MDR逆转剂的研究进展[J].中国药理学通报,2005,21 (5):513-518.
[242]Francois H,Catherine V,Pierre DV,et al.In vitro and in vivoreversal of multidrug resistance by GF120918,an acridonecarboxamide derivative[J].Cancer Res,1993,53(19): 4595-4602.
[243] Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies [J]. Blood, 2004,104(7):1940-51.
[244]Ludwig JA,Szakacs G,Martin SE,et al.Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer [J].Cancer Res.2006,66(9):4808-4815.
[245] Zhou J, Liu M, Aneja R,et al.Reversal of P-glycoprotein-MediatedMultidrug Resistance in Cancer Cells by the c-Jun NH2-Terminal Kinase[J].Cancer Research,2006,66(1):445-52.
[246] Zhang L, Yang Y, Wei XY, et al. Reversing adriamycin resistance of human breast cancer cells by hyperthermia combined with Interferon alpha and Verapamil[J].J Exp Clin Cancer Res,2007 ,26(2):201-207.
[247]Lewandowicz GM,Britt P,Elgie AW,et al.Cellular glutathione content in vitro chemoresponse and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer [J].Gyneco Onceol,2002,85(2);298-304.
[248]Fojo T, Bates S.Strategies for reversing drug resistance [J].Oncogene,2003,22:7512-7523.
[249]Rosario LA, O'Brien ML, Henderson CJ, et al.Cellular response to a glutathione S-transferase P1-1 activated prodrug[J]. Mol Pharmacol, 2000 ,58(1):167-174.
[250]Townsend DM,Shen H,Staros AL,et al. Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells[J].Mol Cancer Ther,2002,1(12):1089-1095.
[251]Versantyoortc HM,Schuurhuis GJ,Pinedo HM,et al.Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells [J].Br J Cancer,1993,68:939-946.
[252] Allen JD, van Loevezijn A, Lakhai JM,et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. [J].Mol Cancer Ther, 2002,1(6): 417-425.
[253]Yasuo Imai,Satomi Tsukahara,Sakiyo Asada,et al. Phytoestrogens /Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2 Mediated Multidrug Resistance [J].Cancer Research,2004,64(12):434-611.
[254]崔恒.卵巢癌的治疗策略[J].继续医学教育.2006,20(8):79-84.
[255]Peter GR.Surgery for recurrent ovarian cancer [J].Semin in Oncol,2000, 27:17-23.
[256] Gungor M,Ortac F,Arvas M,et al.The role of secondary cytoreductive surgery for recurrent ovarian cancer [J].Gynecol Oncol,2005,97(1):74-79.
[257]Hassenburg A,Tong XW,fischer DC,et al. A denovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer 2.5–year follow-up [J].Gynecol Oncol,2002,83(3);549-554.
[258] Deshane J,Cabrera G,Grim JE,et al.Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erB-2 singlechain antibody [J].Gynecol Oncol, 1995, 59:8-11.
[259]Cannon MJ,O Brien TJ,Underwood LJ,et al.Novel targe antigens for dendriteic sell-based immunothetapy against ovarian cancer [J].Expert Rev Anticancer Ther,2002,2(1):97-105.
[260] Hesdorffer C,Ayello J,Ward M,et al.Phase I trial of retrobiral mediated transfer of thehuman MDR1 genes as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell reansplantation [J].Clin Oncol, 1998, 16(1):165-172.
[261] Binyamin L,Assaraf YG,Haus-Cohen M,et al. Targeting an extracel- lular epitope of the human multidrug resistance protein 1 (MRP1) in malignant cells with a novel recombinant single chain Fv antibody [J]. Int J Cancer.2004,110(6):882-890.
[262] Mc Quarrie SA,Mercer JR,Syme A,et al.Preliminary results of nanophaimaceutikal used in the radio immunotherapy of ovarian cancer [J].J Phaim Phaimaceut Sci,2004, 7(4): 29-34.
[263]Wang Z,Cai L,Wang H. Gene therapy of adenovirus mediated CD::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer [J].Gynecol Oncol, 2005, 96(3):643-650.
[264] Boumendjel A,Baubchon Cortay D.Anticancer multidrugresistance medi- ated by MRP1:recent advances in the discovery of re2versal agents [J].Med Res Rev, 2005,25(4):453-472.
[265]韩晓红.肿瘤细胞多药耐药逆转研究[J].北华大学学报(自然科学版),2005,2(6):36-42.
[266]立彦.P-gp介导的肿瘤多药耐药逆转研究进展[J].放射免疫学杂志,2005,18(2):133
[267]李大成,屈艺,刘柏林,等.三种中药制剂Ams-11,Fw-13,Tul-17逆转肿瘤细胞多药耐药性的研究[J].华西医科大学学报,1998,29(1):16.
[268]贾莉,孔力,苗小艳,等.蝎毒逆转K562/ADM细胞多药耐药性的初步研究[J].白血病淋巴瘤,2002,11(2):81-83.
[269]杨孝军,郑飞云,陈必成,等.亚致死量陡脉冲调节人卵巢癌细胞多药耐药的实验研究[J].中华物理医学与康复杂志,2005,27(10):597-560.
[270]白符,冯捷.基因芯片技术在卵巢癌相关基因研究中的应用[J].中国妇产科临床杂志,2004,5(2):157-159.
[271]Kothapalli R,Yoder SJ,Mane S,et al.Microarray results:how accurate are they? [J].BMC Bioinformatics,2002,23(3):22.
[272]胡恭华. DDRT-PCR技术及其在毒理学研究中的应用[J].毒理学杂志,2005, 19(3): 232-235.
[273] Liang P,Pardee AB.Distribution and cloning of eukaryotic mRNAs by means of differential display:refinementsand optimization [J].Nucleic Acids Res,1993,21:3269-3275
[274]王新,兰梅等,不同mRNA差异显示法筛选为癌细胞耐药相关基因的研究[J].肿瘤防治研究.2002,29(3),177-180.
[275] Ylstra B,van den Ijssel P,Carvalho B,et al.BAC to the future or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH) [J]. NucleicAcids Res,2006,34(2):445-450.
[276]彭翼飞,马文丽.寡核苷酸阵列比较基因组杂交技术及其应用[J].中国生物工程杂志,2006,26(10):46-51.
[277]梁丽,丁彦青,石益民.消减抑制杂交及其在肿瘤中的应用[J].癌症.2003,22:997-1000.
[278]罗洁,许辉.基因差异表达分析技术及其在糖尿病研究中的应用[J].实用预防医学, 2005,12(6):1482-1485.
[279] Zhao ZL,Huang X,LiN,et al. Direct cloning of cell differential expression genes with full-length by a new strategy based on the multiple rounds of“long distance”polymerase chain reaction and magnetic beads mediated subtradion [J].J Biotechno1, 1999, 73(1) : 35-4l.
[280] L'Espérance S, Popa I, Bachvarova M,et al.Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors[J]. Int J Oncol. 2006 ,29(1):5-24.
[281]Goto T, Takano M, Sakamoto M,et al.Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers [J].Oncol Rep,2006,15(5):1265-1271.
[282] Li J, Wood WH 3rd, Becker KG,et al.Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells [J].Oncogene,2007,26(20):2860-2872.
[283] Roberts D,Schick J,et al. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells [J].Cancer.2005,92(6):1149-1158.
[284]Varmapr,Hector SM,et al. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10 [J].Oncol Rep, 2005, 14(4):925-932.
[285]Olivero M, Ruggiero T,Saviozzi S,et al.Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin [J].Mol Cancer Ther, 2006, 5(5): 1126-1135.
[286]Komatsu M, Hiyama K, Tanimoto K, et al. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers [J]. Mol Cancer Ther. 2006 ,5(3):767-75.
[287]Verena Materna, Pawel Surowiak,et al. TRAG-3/CSAG2 expression is associated with paclitaxel resistance in ovarian carcinoma cell lines and with clinical outcome in ovarian carcinoma patients[J]. Proc Amer Assoc Cancer Res, 2005( 46):187-194.
[288] Duan Z, Feller AJ, Toh HC, et al.TRAG23,a novel gene isolated from ataxol resistan to varian carcinoma cell line [J].Gene,1999,229(122):75-81
[289] Sigalotti L,Coral S,Altomonate M,et al.Cancer testisantigen expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implication [J].Br J Cancer, 2002,86(6):979-982.
[290]Feller AJ,Duan Z,Penson R,et al.TRAG23,a novel cancer/testisantigen,is overexpresed in the majority of melanoma cell lines and malignant melanoma [J].Anti cancer Res,2000,20(6B):41-47.
[291]Li L,Luan Y,et al. Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis [J]. Oncol Rep, 2005,13(5):793-799.
[292]田方,李春海.mRNA差异显示法筛选卵巢癌细胞株细胞耐药相关基因的初步研究[J].癌症,2000;19(8):744-747.
[293]M Bernardini, CH Lee, B Beheshti, M Prasad,et al. High-resolution mapping of genomicimbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer [J].Neoplasia,2005,7(6): 603-613.
[294]Chaib H, Cockrell EK, Rubin MA, et al.Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis[J]. Neoplasia. 2001,3(1):43-52.
[295]Kuo K C, McCune R A, Gehrke C W, et al. Quantitative reversed-phase high performance liquid chromatographic determination of major and modified deoxyribonucleosides in DNA [J]. Nucleic Acids Res, 1980, 8: 4763-4776.
[296]Fraga M F, Uriol E, Borja D L, et al. High-performance capillary electrophoretic method for the quantification of 5-methyl 2-deoxycytidine in genomic DNA: application to plant, animal and human cancer tissues [J]. Electrophoresis, 2002, 23: 1677-1681.
[297]Oefner, P J, Bonn G K, Huber C G, et al. Comparative study of capillary zone electrophoresis and high-performance liquid chromatography in the analysis of oligonucleotides and DNA. [J]. Chromatogr, 1992, 625(2): 331-3401.
[298]邓大君,邓国仁,吕有勇等.变性高效液相色谱法检测CpG岛胞嘧啶甲基化[J].中华医学杂志, 2001, 80(2), 158–1611.
[299]Wu J, Issa J, Hermen J, et al. Expression of an exogenous eukaryotic DNA methyl transferase gene induces transformation of NIN3T3 ceils [J]. Proc Natl Acad Sci USA, 1993, 90(19): 8891–8895.
[300]Oakeley E J, Podesta A, Jost J P. Developmental changes in DNA methylation of the two tobacco pollen nuclei during maturation [J]. Proc Natl Acad Sci USA, 1997, 94: 11721–11725.
[301]Oakeley E J, Schmitt F, Jost J P. Quantification of 5-methylcytosine in DNA by the chloroacetaldehyde reaction [J]. Biotechniques, 1999, 27(744):748-752.
[302]Frommer M, McDonald L E, Millar D S, et al. A genomic sequencing protocol that yields apositive display of 5-methylcytosine residues in individual DNA strands [J]. Proc Natl Acad Sci USA, 1992, 89: 1827–1831.
[303]Herman J G, Graff J R, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands [J]. Proc Natl Acad Sci USA, 1996, 93(18):9821-9826.
[304]Gonzalgo M L, Jones P A. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE) [J]. Nucleic Acids Res, 1997, 25: 2529–2531.
[305]Maekawa M, Sugano K, Kashiwabara H, et al. DNA methylation analysis using bisulfite treatment and PCR-single-strand conformation polymorphism in colorectal cancer showing microsatellite instability [J]. Biochem Biophys Res Commun, 1999, 262: 671–676.
[306]Aggerholm A, Guldberg P, Hokland M, et al. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia [J]. Cancer Res, 1999, 59: 436-441.
[307]Eads C A, Danenberg K D, Kawakami K, et al. MethyLight: a highthroughput assay to measure DNA methylation [J]. Nucleic Acids Res, 2000, 28: E32.
[308]Huang T H, Perry M R, Laux D E. Methylation profiling of CpG islands in human breast cancer cells [J]. Hum Mol Genet, 1999, 8: 459-470.
[309]Gitan R S, Shi H, Chen C M, et al. Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis [J]. Genome Res, 2002, 12: 158–164.
[310]Clement G., Benhattar J. A methylation sensitive dot blot assay (MS-DBA) for the quantitative analysis of DNA methylation in clinical samples [J]. Clin Pathol, 2005, Feb. 58(2): 155-8.
[311]Nygren A O, Ameziane N, Duarte H M, et al. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences [J]. Nucleic Acids Res, 2005, Aug 16, 33 (14): e128.
[312]Balch C, Huang TH, Brown R, etal. The epigenetics of ovarian cancer drug resistance and resensitization[J]. AmJ Obstet Gynecol ,2004, 191(5): 1552-1572.
[313]Staub J, Chien J, Pan Y, et al.Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance[J]. Oncogene,2007,26:4926-4978.
[314]Jacqueline A. Hall, Jens M. Teodoridis, etal DNA methylation of markers associated with response to chemotherapy in tumor and plasma DNA of ovarian cancer patients[J].AACR Meeting Abstracts, 2006,759-761.
[315]John S. Montgomery, Curtis Balch, Mike Mand, etal Alterations in DNA methylation patterns associated with onset of chemotherapy resistance in ovarian cancer[J].AACR Meeting Abstracts, 2006, 539-541.
[316]Robert Brown, Gillian Gifford, Jim Paul, etal.The acquisition of hMLH1 methylation in plasma DNA following chemotherapy predicts poor survival for ovarian cancer patients[J]. Meeting Abstracts, 2004; 242-246.
[317]Wiley A, Katsaros D, Chen H, etal.Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer. 2006 Jul 15;107(2):299-308.
[318]Chou JL, Su HY, Chen LY, et al.Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.Lab Invest. 2010 ,90(3):414-425.
[319]Swisher EM, Gonzalez RM, Taniguchi T, et al.Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas[J].Mol Cancer. 2009 Jul 14;8:48.
[320]Strathdee G, Vass JK, Oien KA, Siddiqui N, Curto-Garcia J, Brown R.Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy[J].Gynecol Oncol. 2005 ,97(3):898-903.
[321]Horn MP, M?der-Heinemann G, Andrey G,et al.Mutation screening of the medium-chain acyl-CoA dehydrogenase (MCAD) and the ornithine transcarbamylase (OTC) genes by multiplex PCR amplification and sequencing[J]. Clin Chem Lab Med. 2009;47(1):56-59.
[322] Jiang X, Lu C, Gao F,et al.A rapid and simple method for identifying Mycobacterium tuberculosis W-Beijing strains based on detection of a unique mutation in Rv0927c by PCR-SSCP[J]. Microbes Infect. 2009,11(3):419-423.
[323]Sorlie T, Johnsen H, Vu P, et al .Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis[J].Methods Mol Biol. 2005,291:207-216.
[324]Fodde R, Losekoot M. Mutation detection by denaturing gradient gel electrophoresis (DGGE)[J].Hum Mutat, 1994;3(2):83-94.
[325]Zhang DY, Sun TM, Zhang SZ, et al.Mutation detection of PKD2 gene in Chinese by denaturing high-performance liquid chromatograph[J].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004 ,21(3):211-214.
[326]Borresen AL.Mismatch detection using heteroduplex analysis[J].Curr Protoc Hum Genet, 2002 ,Chapter 7:Unit 7.3
[327]Palais B.Quantitative heteroduplex analysis[J]. Clin Chem,2007 ,53(6):1001-1003.
[328]Abe T, Takahashi H, Holmes MD, et al .Ribonuclease A cleavage combined with the polymerase chain reaction for detection of the Z mutation of the alpha-1-antitrypsin gene[J]. Am J Respir Cell Mol Biol. 1989,1(4):329-334.
[329]Whittock NV, Ashton GH, Mohammedi R, et al Comparative mutation detection screening of the type VII collagen gene (COL7A1) using the protein truncation test, fluorescent chemical cleavage of mismatch, and conformation sensitive gel electrophoresis[J]. J Invest Dermatol, 1999 ,113(4):673-686.
[330]Yang DY, Fushimi H, Cai SQ,et al. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and amplification refractory mutation system (ARMS) analyses of medicinally used Rheum species and their application for identification of Rhei Rhizoma. Biol Pharm Bull. 2004,27(5):661-669.
[331]Pieri Pde C, Nogueira Jde A, et al . A duplex allele-specific amplification PCR to detect SMN1 deletion[J].Genet Test Mol Biomarkers, 2009 ,13(2):205-208.
[332]Perego P, Giarola M, Righetti SC, et al . Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems[J].Cancer Res, 1996,56(3):556-562.
[333]Kawasaki M, Nakanishi Y, Kuwano K, et al . The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer [J] . Clin Cancer Res, 1997, 3(7):1195-1200.
[334]Salani R, Kurman RJ, Giuntoli R , et al.Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance[J].Int J Gynecol Cancer. 2008,18(3):487-491.
[335]Mustea A, Sehouli J, Fabjani G, et al. Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study[J] Anticancer Res. 2007 May-Jun;27(3B):1527-1530.
[336]B?hnke A, Jung J, Taubert H, et al.Both somatic and germline genetics of the TP53-pathway influence ovarian cancer incidence and survival[J]. Verh Dtsch Ges Pathol. 2007;91:233-242.
[337]Gadducci A ,Cosio S,M uraca S,et al.Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer:Biological data and clinical implications [J].Eur J Gynaecol Oncol,2002,23(5):390-396.
[1]Watanabe Y, Ueda H, Etoh T, et al.A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer[J].Anticancer Res, 2007,27(3B): 1449-1452.
[2]Staub J, Chien J, Pan Y, et al.Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance[J]. Oncogene 2007,26 (34):4926–4978.
[3]栾英姿,李力,黎丹戎,等.五种卵巢癌耐药细胞系的建立及其部分耐药相关基因的表达[J].中华妇产科杂志,2004, 39(6):403-407.
[4]唐兆前,李力,张玮等.改良2 -△△CT法分析RNASET2基因在卵巢癌卡铂耐药细胞系中的差异表达[J]。肿瘤预防与治疗,2009,22(3):242-245.
[5]Soong R., Ruschoff,J. and Tabiti,K. Detection of colorectal micrometastasis by quantitative RT–PCR of cytokeratin 20 mRNA[J]. Roche Diagnostics internal publication,2000.
[6]张文晶,李红霞,宋磊,等.应用基因芯片技术筛选卵巢癌紫杉醇耐药差异表达基因[J].肿瘤防治研究,2006,33(1):32-35.
[7]VASE P A. Resistance to chemotherapy in advanced ovarian cancer :mechanisms and current strategies[J] . Br J Cancer , 2003 , 89 (Suppl3) : S23.
[8]曾益心肿瘤学[M].第二版第二次印刷,北京:人民卫生出版社,2003:97
[9]Fraser M, Bai T, Tsang BK.Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function[J]. Int J Cancer. 2008 ,122(3):534-546.
[10]Jin X, Burke W, Rothman K, et al.Resistance to p53-mediated growth suppression in human ovarian cancer cells retain endogenous wild-type p53[J]. Anticancer Res. 2002 ,22(2A):659-664.
[11]Wu H, Cao Y, Weng D, et al.Effect of tumor suppressor gene PTEN on theresistance to cisplatin in human ovarian cancer cell lines and related mechanisms[J]. Cancer Lett. 2008 ,28;271(2):260-271.
[12]袁才佳,聂新民.应用Real-time PCR对基因芯片结果的验证分析[J].现代医药卫生.2007,23(21):3187-3189.
[13]Tseng GC, Oh MK, Rohlin L,et al. Issues in cDNA microarray analysis: quality filtering, channel normalization,models of variations and assessment of gene effects[J] .Nucleic Acids Res, 2001, 29(12): 2549-2557.
[14]罗瑶,许宏,李瑶,等.表达谱基因芯片的可靠性验证分析[J].遗传学报,2003 , 30 (7) : 611-618.
[15]Yue H,Eastman P S,Wang B B,Minor J,et al.An evaluation of the performance of cDNA microarrays for detecti changes in global mRNA expression[J].Nucleic Acids Res,2001, 29(8): E41-1.
[16]Chaib H, Cockrell EK, Rubin MA, et al.Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis[J]. Neoplasia. 2001,3(1):43-52.
[17]Hembruff SL, Villeneuve DJ, Parissenti AM. The optimization of quantitative reverse transcription PCR for verification of cDNA microarray data[J]. Anal Biochem. 2005 ,345(2):237-249.
[18]Azim AC, Knoll JH, Marfatia SM, et al .DLG1: chromosome location of the closest human homologue of the Drosophila discs large tumor suppressor gene[J]. Genomics. 1995,30(3):613-616.
[19]Wang JC, Lv H, Gao X.et al.Expression and distribution of Dlg1 during meiotic maturation in mouse oocytes[J]. Biochem Biophys Res Commun. 2009. [Epub ahead of print]
[20]Vieira V, de la Houssaye G, Lacassagne E, et al.Differential regulation of Dlg1, Scrib, and Lgl1 expression in a transgenic mouse model of ocular cancer[J].2008,14:2390-2403.
[21]Fuja TJ, Lin F, Osann KE, et al.Somatic mutations and altered expression of the candidate tumor suppressors CSNK1 epsilon, DLG1, and EDD/hHYD in mammary ductal carcinoma[J]. Cancer Res. 2004,64(3):942-51.
[22]Guo W J, ZengM S, Yaday A, et al. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells [J]. Cancer Res,2007,67(11):5083-5089.
[23]Miyazaki K, Inoue H, Onai N, et al .Chemokine-mediated thymopoiesis is regulated by a mammalian Polycomb group gene, mel-18[J]. Immunol Lett. 2002,80(2):139-143.
[24]Li YJ, Chen ZC. Molecular cloning and characterization of LCRG1 a novel gene localized t o the tumor supp ress or locus D17S8002 D17S930 [ J ]. Cancer Lett, 2004, 209 (1) : 75-85.
[1] Balch C, Huang TH, Brown R, et al. The epigenetics of ovarian cancer drug resistance and resensitization[J]. AmJ Obstet Gynecol ,2004, 191(5):1552-1572.
[2] Staub J, Chien J, Pan Y, et al.Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance[J]. Oncogene,2007, 26(34):4969-4978.
[3] Watanabe Y, Ueda H, Etoh T, et al. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer[J].Anticancer Res, 2007, 27(3B): 1449-1452.
[4]Singal R,Ginder G D.DNA methylation[J],1999,93(12):4059-4070.
[5]Lund A H , Lohuizen MV.Epigenetics and Cancer[J].Genes Dev , 2004 ,18(19):2315-2335.
[6]Li M, Balch C, Montgomery JS, et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer[J].Li MBMC Med Genomics, 2009 , 8;2:34.
[7]Staub J, Chien J, Pan Y, et al. Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance[J] . Oncogene, 2007,26( 34) : 4969-4978.
[8]VASE P A. Resistance to chemotherapy in advanced ovarian cancer :mechanisms and current strategies[J] . Br J Cancer , 2003 , 89 (Suppl3) : S23.
[9]冯作化.医学分子生物学[M].第1版.北京:人民卫生出版社,2005:109.
[10]Chen H, Ye F, Zhang J,et al. Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma[J].Eur J Gynaecol Oncol,2007,28(6):464-467.
[11]Havrilesky L, Darcy M, Hamdan H, et al.Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study[J]. J Clin Oncol, 2003,21(20):3814-3825.
[12]M Mandail-V. I KonishiK T Komatsu. Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progressionand nm23 gene expression[J] .Britsh J burnal Cancer ,1995, 72:691-695.
[13]Chen H, Ye F, Zhang J, et al. Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma[J]. Eur J Gynaecol Oncol, 2007,28(6):464-467.
[14]Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell,2004;116:281-297.
[15]Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer[J]. Nat Rev Cancer,2006;6:259-269.
[16]Calin GA, Croce CM. MicroRNA signatures in human cancers[J]. Nat Rev Cancer,2006;6:857-866.
[17] Lee RC, Feinbaum RL, Ambros V . The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J].Cell, 1993 ,75(5):843-854.
[18]Liu J, Valencia-Sanchez MA, Hannon GJ, et al. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies[J].Nat Cell Biol, 2005 , 7(7):719-723.
[1]冯作化,医学分子生物学[M],第一次印刷第一版,北京:人民卫生出版社, 2005, 109
[2] Mandail-V M,KonishiK IT Komatsu,et al.Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression[J]. Britsh Journal of Cancer,1995, 72(3):. 691-695
[3]Schuldes H, Dolderer JH, Zimmer G, et al. Reversal of multidrug resistance and increase in plasma membrane fluidity in CHO cells with R-verapamil and bile salts[J]. Eur J Cancer ,2001,37(5):660-667.
[4]Samimi G, Fink D, Varki NM, et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy[J]. Clin Cancer Res. 2000 ,6(4):1415-1421.
[5]Damia G, Guidi G, D'Incalci M. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines[J]. Eur J Cancer, 1998 ,34(11):1783-1788.
[6]DabholkarM, Thornton K, Vionnet J, et al. Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues[J]. Biochem Pharmacol .2000 ,60(11):1611-1619.
[7]Mujoo K, Zhang L, Klostergaard J, et al. Emergence of cisplatin-resistant cells from the OVCAR-3 ovarian carcinoma cell line with p53 mutations, altered tumorigenicity, and increased apoptotic sensitivity to p53 gene replacement[J]. Int J Gynecol Cancer ,2000 ,10(2):105-114.
[8]Roy G, Horton JK, Roy R, et al. Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins[J]. Oncogene, 2000,19(1):141-150.
[9] Bazzett LB, Watkins CS, Gercel-Taylor C, et al. Modulation of proliferation and chemosensitivity by procathepsin D and its peptides in ovarian cancer. Gynecol Oncol 1999 Aug;74(2):181-187
[10]Appierto V, Cavadini E, Pergolizzi R, et al. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line[J]. Br J Cancer.2001, 84(11):,1528-1534.
[11] Kiyozuka Y, Yamamoto D, Yang J, et al. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells[J]. Anticancer Res ,2000 ,(1A):203-212.
[12]Ottone F, Miotti S, Bottini C, et al. Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines[J]. Br J Cancer 1997;76(1):77-82.
[13]Ogiso Y, Tomida A, Lei S, et al. Proteasome inhibition circumvents solid tumor resistanceto topoisomerase II-directed drugs[J]. Cancer Res , 2000 ,60(9):2429-2434
[14]Gadducci A ,Cosio S,M uraca S,et al.Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer:Biological data and clinical implications [J].Eur J Gynaecol Oncol,2002,23(5):390-396.
[15]Righetti SC, Perego P, Corna E, et al. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection[J]. Cell Growth Differ.1999 ,10(7):473-478.
[16]Perego P, Giarola M, Righetti SC, et al . Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems[J].Cancer Res. 1996,56(3):556-62.
[17]Campomenosi P,Salis S,Lindqvist C,etal.Characterization of RNASET2,the first human member of the Rh/T2/S family of glycoproteins[J]. Arch Biochem Biophys. 2006, 449(1-2):17-26.
[18]Acquati F, Possati L, Ferrante L, etal. Tumor and metastasis suppression by the human RNASET2 gene[J]. Int J Oncol. 2005,26(5):1159-1168.
[19]Monti L, Rodolfo M,Lo Russo G,etal. RNASET2 as a tumor antagonizing gene in a melanoma cancer model[J].Oncol Res. 2008, 17(2):69-74 .
[20]Lin F, Shi J, Liu H, et al. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus[J].Am J Clin Pathol. 2008 ,129(4):592-605.
[21]Osada R, Horiuchi A, Kikuchi N,et al. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma[J]. Hum Pathol. 2007 ,38(9):1310-1320.
[22]Wang Y, Pakunlu RI, Tsao W, et al .Bimodal effect of hypoxia in cancer: role of hypoxia inducible factor in apoptosis[J]. Mol Pharm. 2004,1(2):156-165.
[23]Lee S, Garner EI, Welch WR, et al. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma[J].Gynecol Oncol. 2007 ,106(2):311-317.
[24]Hasina R, Pontier AL, Fekete MJ, et al.NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype[J].Oncogene. 2006,25(4):588-598.
[25]Ripperger T, von Neuhoff N, Kamphues K,et al. Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle-cell lymphomas.Haematologica[J]. 2007,92(4):460-468.
[26]Myagmar BE, Umikawa M, Asato T, et al. PARG1, a protein-tyrosine phosphatase-associated RhoGAP, as a putative Rap2 effector[J]. Biochem Biophys Res Commun. 2005 ,329(3):1046-1052.
[27]Katoh Y, Katoh M. Identification and characterization of ARHGAP27 gene in silico[J]. Int J Mol Med. 2004 ,14(5):943-947.
[28]Garkavtsev I, Demetrick D, Riabowol K. Cellular localiza-tion and chromosome mapping of a novel candidate tumorsuppressor gene (ING1)[J]. Cytogenet Cell Genet, 1997,76(34): 176-178.
[29]Zeremski M, Horrigan SK, Grigorian IA, et al. Localizationof the candidate tumor suppressor gene ING1 to human chro-mosome 13q34[J]. Somat Cell Mol Genet, 1997, 23(3):233-236.
[30]Gunduz M, Ouchida M, Fukushima K, et al. Genomic structure of the human ING1 gene and tumor-specific mutation detected in head and neck squamous cell carcinomas[J]. Cancer Res, 2000,60(12):3143-3146.
[31]Toyama T, Iwase H, Wastson P, et al. Suppression of ING1 expression in sporadic breast cancer[J]. Oncogene,1999,18(37):5187-5193.
[32]Chen L, Matsubara N, Yoshino T, et al. Genetic alterations of candidate tumor suppressor ING1 in human esophageal squamous cell cancer[J]. Cancer Res, 2001,61(11):4345-4349.
[33]Oki E, Maehara Y, Tokunaga E, et al. Reduced expression of p33/ING1 and the relationship with p53 expression in human gastric cancer[J]. Cancer Lett,1999, 147(1-2):157-162.
[34]Shen DH, Chan KY, Khoo US, et al. Epigenetic and genetic alterations of p33ING1b in ovarian cancer[J]. Carcinogenesis,2005,26(4):855-863.
[35]梁燕华,何平平,杨森.多发性家族性毛发上皮瘤致病基因的确定[J].中华皮肤科杂志, 2005, 38(2): 71-73.
[36]Hildebrandt T, Preiherr J, TarbéN, et al. Identification of THW, a putative new tumor suppressor gene[J].Anticancer Res. 2000 ,20(5A):2801-2809.
[37]Singaravelu K, Devalaraja-Narashimha K, Lastovica B, et al. PERP, a p53 proapoptotic target, mediates apoptotic cell death in renal ischemia[J]. Am J Physiol Renal Physiol. 2009,296(4):847-858.
[38]Attardi LD, Reczek EE, Cosmas C, et al. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family[J].Genes Dev. 2000 ,14(6):704-718.
[39]Sarkar S, Pollack BP, Lin KT, et al. hTid-1, a human DnaJ protein, modulates the interferon signaling pathway[J].J Biol Chem. 2001 , 76(52):49034-49042.
[40] Paraoan L, Gray D, Hiscott P,et al.Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type[J]. Exp Eye Res. 2006 ,83(4):911-919.
[41]Edwards KM,Edwards KM, Münger K,et al.Depletion of physiological levels of the human TID1 protein renders cancer cell lines resistant to apoptosis mediated by multiple exogenous stimuli[J] .Oncogene. 2004 ,23(52):8419-8431.
[1]Ducasse M, Brown M A. Epigenetic aberrations and cancer[J].Mol Cancer,2006,5(1):60-75.
[2]Fegers I, Kob R, Eckey M, et al .The tumor suppressors p33ING1 and p33ING2 interact with alien in vivo and enhance alien-mediated gene silencing[J]. J Proteome Res.2007,6(11):4182-4188.
[3]Eckey M, Tenbaum SP, Mu?oz A, et al.Mixed lineage kinase 2 enhances trans-repression of Alien and nuclear receptors[J]. Mol Cell Endocrinol. 2003 ,213(1):71-78.
[4]Tenbaum SP, Papaioannou M, Reeb CA, et al.Alieninhibits E2F1 gene expression and cell proliferation[J]. Biochim Biophys Acta. 2007,1773(9):1447-1454.
[5]Vieyra D, Senger DL, Toyama T,et al.Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors[J]. Clin Cancer Res. 2003,9(16 Pt 1):5952-5961.
[6]Kameyama K, Huang CL, Liu D,et al .Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients[J]. Clin Cancer Res. 2003,9(13):4926-4934.
[7]Zhu Z, Lin J, Qu JH, et al .Inhibitory effect of tumor suppressor p33(ING1b) and its synergy with p53 gene in hepatocellular carcinoma[J]. World J Gastroenterol. 2005,11(13):1903-1909.
[8]Shen DH, Chan KY, Khoo US, et al .Epigenetic and genetic alterations of p33ING1b in ovarian cancer[J]. Carcinogenesis. 2005 ,26(4):855-863.
[9] Hildebrandt T, Preiherr J, TarbéN, et al. Identification of THW, a putative new tumor suppressor gene[J].Anticancer Res. 2000 ,20(5A):2801-2809.
[10]Hasina R, Pontier AL, Fekete MJ, et al.NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype[J]. Oncogene. 2006,25(4):588-598.
[11]Mankame TP, Zhou G, Lingen MW.Identification and characterization of the human NOL7 gene promoter[J]. Gene. 2010,456(1-2):36-44.
[12]Edwards KM, Munger K.Depletion of physiological levels of the human TID1 protein renders cancer cell lines resistant to apoptosis mediated by multiple exogenous stimuli[J]. Oncogene. 2004 ,23(52):8419-8431.
[13] Kim SW, Hayashi M, Lo JF, et al .Tid1 negatively regulates the migratory potential of cancer cells by inhibiting the production of interleukin-8[J]. Cancer Res. 2005 ,65(19):8784-8791.
[14]梁燕华,何平平,杨森.多发性家族性毛发上皮瘤致病基因的确定[J].中华皮肤科杂志,2005, 38(2): 71-73.
[15] Hutti JE, Shen RR, Abbott DW,et al.Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation[J].Cancer Res. 2004 ,64(15):5113-5117.
[16] Salhi A, Bornholdt D, Oeffner F, et al.Multiple familial trichoepithelioma caused by mutations in the cylindromatosis tumor suppressor gene[J].Mol Cell. 2009,34(4):461-72.
[17]李孟达,李玉洁,黄永文,等.影响上皮性卵巢癌远期疗效的因素分析[J].癌症杂志.2004,23(11):1306-1310.